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Abstract
HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K (HNRNPK) OVEREXPRESSION
AND ITS INTERACTION WITH RUNX1 IN ACUTE MYELOID LEUKEMIA

Marisa Janelle Lynne Aitken, B.S.
Advisory Professor: Sean Post, Ph.D.

Acute myeloid leukemia (AML) is an often devastating hematologic malignancy with 5year overall survival lingering near 20%. Acquiring a deeper understanding of molecular

underpinnings of leukemogenesis will provide a basis for developing more effective
therapeutic strategies for patients with AML.
Here, we identified overexpression of hnRNP K as a recurrent abnormality in a subset
(~20%) of AML patients. High levels of this RNA-binding protein associated with inferior clinical

outcomes in de novo AML. Thus, to evaluate its putative oncogenic capacity in myeloid
disease, we overexpressed hnRNP K in murine hematopoietic stem and progenitor cells isolated
from fetal liver cells (FLCs). We revealed that hnRNP K-overexpression alters self-renewal
capacity and differentiation potential of these cells in vitro. Such findings were recapitulated
in vivo, as murine recipients of hnRNP K-overexpressing FLCs developed fatal
myeloproliferative phenotypes.

To elucidate mechanisms by which hnRNP K overexpression causes myeloid
neoplasia, we took an unbiased approach utilizing RNA-immunoprecipitation sequencing
(fRIP-Seq). Among RNA transcripts interacting with hnRNP K was RUNX1—a pivotal
transcriptional regulator of definitive hematopoiesis commonly mutated or translocated
in AML. Consensus hnRNP K binding sites were identified in the 5’ UTR and near the 3’
viii

splice site in intron 5-6 of RUNX1. Fluorescence anisotropy studies confirmed these
interactions were direct, and abrogated when hnRNP K binding sites within RUNX1 were
mutated. Manipulating hnRNP K expression in human cell lines and murine FLCs
substantially altered RUNX1 splicing surrounding exon 6. RNA-sequencing of FLCs
confirmed these data, exposing RUNX1 as a significantly differentially spliced entity in
the context of hnRNP K overexpression. Importantly, the protein product of this spliced
product (RUNX1ΔEx6) exhibited disparate transcriptional activity in reporter assays
compared to full-length RUNX1. Furthermore, we identified KH3 as the hnRNP K domain
most critical for these splicing alterations; deletion of KH3 markedly abrogated hnRNP K
overexpression phenotypes in vitro.
In sum, we established hnRNP K as an oncogene in myeloid leukemia that binds
RUNX1 RNA, altering its splicing and subsequent transcriptional activity. These findings
shed light on a mechanism of myeloid leukemogenesis, paving the way for drug
discovery efforts to improve outcomes for patients with this disease.
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Chapter 1
Introduction
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1.1 Acute myeloid leukemia
Acute myeloid leukemia (AML) is a devastating hematologic malignancy wherein normal
hematopoiesis is superseded by rapid proliferation of immature myeloid cells. In adults, AML is
the most common acute leukemia, and the annual incidence in the United States ranges from 35 cases per 100,000 people.1, 2 While the median age of diagnosis is 70 years, this disease is
also found in children and young adults.3, 4 AML is responsible for most leukemia-related deaths
in the United States, where over 10,000 patients died from this disease in 2019 alone.5
Hematopoiesis, the process of blood development, occurs in the bone marrow. Through
exquisitely orchestrated processes of self-renewal and differentiation, hematopoietic stem cells
(HSCs) eventually give rise to all of the cellular components of blood.6 These include 1) red
blood cells (RBCs), responsible for delivery of oxygen to tissues, 2) white blood cells (WBCs),
used to combat infection, and 3) platelets, which aid in blood clotting, or hemostasis. In leukemia,
aberrations in HSCs, or their slightly more mature progeny, result in unrestrained proliferation of
immature WBCs. These rapidly dividing cells fill the bone marrow, usurping the space in which
normal blood cells are made.

As these malignant cells crowd out normal hematopoiesis,

production of RBCs, WBCs, and platelets becomes severely compromised.

This leads to

anemia, leukopenia, and thrombocytopenia, respectively. These are responsible for the major
clinical manifestations of the disease—all of which can be life threatening: infection (due to
leukopenia, specifically neutropenia), bleeding (due to thrombocytopenia), and organ failure (due
to anemia).7
AML derives its name from the lineage of cells from which it stems. White blood cells are
grossly categorized into either myeloid or lymphoid lineages. Acute leukemias of lymphoid
lineage are referred to as acute lymphoid leukemias (ALL), while those of myeloid lineage are
acute myeloid leukemia (AML).
AML is characterized by several recurrent chromosomal and genetic aberrations. These
provide insight not only into the underlying biology of the disease, but can also be used in some
2

instances to provide prognostic information and to guide treatment decisions. For example, a
subtype of AML known as acute promyelocytic leukemia (APL) is defined by a translocation
between chromosomes 15 and 17 (t(15;17)).8, 9 This chromosomal abnormality results in the
formation of a fusion protein known as PML-RARA, which largely contributes to the disease.10, 11
Prior to the late 1980s, APL was a universally fatal subtype of AML.12 Due to concerted efforts
to understand the biology of PML-RARA, incredibly effective APL treatments have been tailored,
and this disease is now almost universally curable (>97% 5-year overall survival).13, 14
Another subtype of AML with generally fair prognosis includes those with recurrent
cytogenetic abnormalities are associated with core-binding factor AML (CBF-AML). This subset
of AML includes t(8;21) and inv(16), which lead to the creation of the fusion genes RUNX1RUNX1T1 and CBFB-MYH11, respectively.15-18 CBF-AML has a high complete response rate
(80-90%) to standard chemotherapy with 3 days of anthracycline along with 7 days of cytarabine
(3+7).19-22 In addition, 5-year overall survival (OS) in CBF-AML is more than 60% in younger
patients.19, 20 Even in older patients with CBF-AML, 5-year OS is near 30%.23
Unfortunately, not all subtypes of AML have seen this same progress. Taken as a whole,
patients under age 60 have a 5-year survival of approximately 40%, while older patients have a
much lower (~10%) 5-year survival.3, 24, 25
Mutations in AML can also be used for prognostication and/or to tailor therapy. For example,
NPM1 mutations (in the absence of co-occurring mutant FLT3) or biallelic CEBPA mutations
have been shown to confer a relatively fair prognosis.26, 27 Patients harboring other mutations,
such as those in FLT3, IDH1, or IDH2 can now benefit from the recently FDA-approved small
molecule inhibitors of these mutant proteins.28-31 While these new therapies are improving patient
outcomes, many patients lack such targetable mutations.32-34 In addition, patients treated with
these inhibitors are often still at risk for relapse.28-31 This highlights the need to further understand
the molecular underpinnings of AML such that alternative, effective therapeutic options can be
developed.
3

1.2 Heterogeneous nuclear ribonucleoprotein K (hnRNP K)
The gene encoding hnRNP K (HNRNPK) resides on chromosome 9q21.32. Deletions of
chromosome 9q (del(9q)) are recurrent cytogenetic abnormalities observed in approximately 2%
of patients with AML.35-37 Scattered mutations in this gene have also been identified in AML,
albeit at an exceedingly low frequency (~1%).32-34 While these mutations have not been formally
characterized, it has been suggested that they result in haploinsufficiency of hnRNP K.38
Functionally, hnRNP K is a renaissance (wo)man of proteins. It has been implicated in a
wide variety of normal cellular functions, including signal transduction39-43, chromatin
remodeling44-47, transcription48-54, RNA splicing55-59, mRNA stability60-62, and translation54, 63-69.
Not surprisingly, homozygous Hnrnpk knockout is embryonic lethal in mice, supporting its role as
an essential gene.53 This broad functionality of hnRNP K is largely due to its composite protein
domains. A nuclear localization signal (NLS) and a nuclear shuttling domain (KNS) allow hnRNP
K to move bi-directionally between the cytoplasm and nucleus.70, 71 The K-interactive (KI) domain
is largely responsible for the interaction between hnRNP K and other proteins.72, 73 In addition,
three K homology (KH) domains are located throughout the protein, which recognize RNA and
single-stranded DNA.74 KH1 and KH2 are located at the amino terminus, while KH3 resides at
the carboxy terminus—separated by a large unstructured region, including the KI domain.72-74
These domains are depicted in Figure 1.

Figure 1: Schematic of hnRNP K: Each domain is indicated. Diagram is not to scale. NLS:
nuclear localization signal; KH: K homology domain; KI: K interactive domain; KNS: K nuclear
shuttling.
4

hnRNP K has been implicated in a variety of malignancies.

For example, our group

developed a mouse model to demonstrate that HNRNPK is the haploinsufficient tumor
suppressor at the recurrently deleted 9q locus in AML.53 In contrast to this observation, several
clinical studies have observed that increased hnRNP K expression is correlated with advanced
disease and poor clinical outcomes in several malignancies including breast, pancreatic, and
colorectal cancers, among others.75-82 Indeed, we recently identified overexpression of hnRNP
K associated with substantially inferior overall survival in a subset of patients with diffuse large
B-cell lymphoma (DLBCL), regardless of subtype.83 Critically, when we generated a mouse
model of B-cell specific hnRNP K overexpression, mice developed B-cell lymphoma—thus
formally demonstrating that hnRNP K is an oncogene in B-cell malignancies when
overexpressed.83

1.3 RUNX1
RUNX1 (also called AML1, CBFa2, or PEBP2aB) is a pivotal hematopoietic transcription
factor.84 Homozygous Runx1 knockout is embryonic lethal in mice due to absence of definitive
hematopoiesis and propensity to hemorrhage.85 Runx1 heterozygotes have diminished erythroid
and myeloid progenitor cells.85 When Runx1 is conditionally deleted in adult mice, significant
hematopoietic alterations are observed, including inefficient production of platelets and common
lymphocyte progenitors.86 These mice also display a myeloproliferative phenotype.86
RUNX1 is located on chromosome 21 in humans and chromosome 16 in mouse. Two
alternative promoters—distal (P1) and proximal (P2)—control expression of RUNX1 in
vertebrates.87 Isoforms arising from P1 and P2 have different 5’ untranslated regions (UTRs)
and coding sequences at the amino terminus, but are otherwise identical in their full-length
forms.87 RUNX1C is the major isoform transcribed from P1.87 Utilization of P2 results in the
formation of RUNX1B.87 In primates, alternative exon usage also results in RUNX1A, which
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lacks the 203 N-terminal amino acids present in RUNX1B.87-90 In mice, a functional ortholog of
RUNX1A is generated by use of an extended terminal exon, referred to as Runx1bEx6e.88
All of these major RUNX1 isoforms share a conserved runt-homology domain (RHD), which
is responsible for sequence-specific DNA recognition and binding, as well as heterodimerization
with CBFb.91,

92

The longer isoforms (RUNX1B and RUNX1C) also share a transactivation

domain (TAD) and inhibitory domain, where protein-protein interactions occur that can influence
the transcriptional activity of RUNX1.93, 94
While all RUNX1 isoforms have been identified throughout various temporal stages in
hematopoiesis, RUNX1B predominates in the adult.95 RUNX1C is mostly present early in
development, as definitive HSCs emerge95, but is re-expressed in adult B-cells, where it inhibits
proliferation96. In contrast to the embryonic lethality observed in complete Runx1 knockout mice,
knockout of only the P1 locus (encoding this C isoform) does not result in an overt phenotype.86,
97

Throughout this work, we refer to RUNX1B as simply “RUNX1” unless otherwise specified.
Overexpression of human RUNX1A in mouse models leads to lymphoid leukemia98,

expansion of hematopoietic stem and progenitor cell populations99, and enhanced engraftment
into recipient mice.99, 100 In striking contrast, overexpression of the longer isoforms of RUNX1
leads to altered hematopoietic differentiation, favoring monocytes over granulocytes101,
decreased engraftment potential95, 99, and p53-dependent senescence102, 103.
In leukemias of various lineages, RUNX1 is a common target of chromosomal translocations
or mutations. Indeed, RUNX1 was originally identified in the context of the t(8;21) translocation
in AML (thus its alias, AML1).104 Other recurrent translocations affecting RUNX1 include t(3;21)
in myelodysplastic syndrome (MDS) and therapy-related AML (t-AML)105, and t(12;21) in pediatric
ALL106, though dozens more have been reported107. Somatic point mutations in RUNX1 are also
evident in AML, ALL, and MDS108,

109

, and are associated with high-risk disease110-115.

Furthermore, germline RUNX1 mutations are associated with familial platelet disorder with
associated myeloid malignancy (FPDMM).116
6

1.4 RNA Splicing and its role in hematologic malignancies
Though only approximately 20,000 protein-coding genes have been identified in the human
genome117, 118, many more proteins have been observed in cells119, 120. In fact, the vast majority
of these genes are thought to give rise to multiple isoforms.121, 122 Such entities are occasionally
referred to as “spliceoforms”, as it is now widely accepted that alternative splicing is the major
mechanism behind this phenomenon.
Early descriptions and imaginations of alternative splicing were documented in the 1970s
based on the observed piece-like structure of bacterial genes.123, 124 (These references are worth
reading, as they offer intriguing historic insight via fascinating speculations on a phenomenon
that was, at the time, almost completely enigmatic.) It is now appreciated that splicing is required
for the maturation of the vast majority of mRNAs, and occurs in the nucleus where non-coding
introns are excised from pre-mRNA to allow for a continuous stretch of protein-coding exons in
a mature transcript prior to translation.121, 122 Use of alternative splice sites results in selective
use of exons.125 This contributes to the immense proteomic diversity observed in cells.119, 120
Large molecular complexes known as the major and minor spliceosome mediate the RNA
splicing process.125-127

These are comprised of several small nuclear ribonucleoprotein

complexes (snRNPs; consisting of small RNAs complexed with proteins): U1, U2, U4, U5, and
U6 in the major spliceosome125, and U5, U11, U12, U4, and U6 in the minor spliceosome126, 128.
As transcription occurs, the U1 snRNP binds the 5’ splice site (5’ss; located between the
upstream exon and intron).125, 126, 129 The 3’ss is soon bound by U2 auxiliary factors (U2AFs).126,
129

Shortly thereafter, the U2 snRNP binds sequence motifs at the 3’ splice site (3’ss; flanking the

intron and downstream exon).125, 126 Finally, U4/U5/U6 snRNPs are recruited, the fully assembled
spliceosome assumes an active conformation, and two sequential transesterification reactions
occur, resulting in intron excision and ligation of adjacent exons.125
Promoters and repressors of splicing can further impact splicing outcomes. Serine-argininerich proteins (SR proteins) and heterogeneous nuclear ribonucleoproteins (hnRNPs) are
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canonically classified as promoters and repressors, respectively.130-134 However, their impact on
splicing can vary depending on a variety of factors, including the relative location within the premRNA in which they bind, cellular context, expression level or mutation of the splicing factor,
etc.135-138
Alterations in RNA splicing have been increasingly recognized in numerous solid and
hematologic malignancies.

In particular, mutations in genes encoding splicing factors are

common in MDS and AML.139-141 The most common of these mutated splicing factors are
serine/arginine-rich splicing factor 2 (SRSF2), splicing factor 3B subunit 1 (SF3B1), U2 small
nuclear auxiliary factor 1 (U2AF1), and zinc finger RNA-binding motif and serine/arginine-rich 2
(ZRSR2), all of which contribute to recognition of the 3’ss.139-141 These mutations are invariably
mutually exclusive with one another. With the exception of ZRSR2, the observed mutations are
heterozygous and affect specific amino acid residues.32-34 Mutations in ZRSR2 confer loss of
function, whereas mutations in the remainder of these genes confer gain of function and/or
altered functionality.142 Individual splicing factor mutations have been correlated with specific
subtypes of myeloid malignancies143, indicating that differentially altered splicing can result in
varied phenotypic consequences. For example, Srsf2P95H mice develop features consistent with
MDS, such as leukopenia, morphologic dysplasia, and increased numbers of myeloid progenitor
cells.144 While U2af1S34F mice do not develop the same dysplasia, though leukopenia and
increased myeloid progenitor cells are evident.145
Even in the absence of these splicing mutations, aberrant splicing in myeloid malignancies
has been described.146 This is likely due in part to the fact that dysregulated splicing can give
rise to oncogenic protein isoforms.147, 148 Understanding the factors involved in aberrant splicing
as well as the consequences of aberrant protein isoform expression are thus important in more
deeply understanding disease.

8

1.5 hnRNP K and splicing
hnRNP K has been shown to influence the splicing of several genes.56, 58, 59, 149-151 This is in
part due to its interactions with splicing factors, such as SRSF7 (also called 9G8) and SRSF3
(also called SRp20).46 In hepatocellular carcinoma, hnRNP K has been shown to alter splicing
of G6PD in opposite directions depending on its interacting protein partners.152
As a poly(C) binding protein, hnRNP K can bind polypyrimidine tracts in the proximity of both
3’ and 5’ splice sites.56,

74, 153

In the case of chicken b-tropomyosin pre-mRNA, hnRNP K

promotes splicing of an alternative exon 6A.55

Likewise, inclusion of MRPL33 exon 3 is

dependent on elevated levels of hnRNP K.150 Contrastingly, hnRNP K acts as a splicing inhibitor
in the case of Bcl-Xs, preventing production of this pro-apoptotic entity.58 Thus, even in the case
of direct RNA-binding, hnRNP K can have variable effects on pre-mRNA splicing.154
Indirectly, hnRNP K can alter splicing by regulating expression of splicing factors. This is
exemplified in gastric cancers, where hnRNP K transcriptionally upregulates of SRSF1, which in
turn alters splicing of CD44.151
Together, these observations demonstrate that hnRNP K can directly and indirectly influence
splicing in a context-dependent manner.

1.6 Regulation of RUNX1 by splicing
Like the majority of protein-coding genes with more than one exon, RUNX1 pre-mRNA
undergoes splicing. As discussed in section 1.3, the isoforms RUNX1A and RUNX1B arise due
to alternative splicing. However, the mechanisms underlying the specifics of this splicing have
not been fully elucidated. Another isoform of RUNX1 lacks an internal 64 amino acid residues
(corresponding to exon 6), and has been identified in mouse and human.88, 93, 149, 155 In ovarian
cancer, this isoform (herein called RUNX1DEx6) has been correlated with inferior outcomes.155
Poly(C) binding proteins, including PCBP2 and hnRNP K have been shown to play a role in this
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splicing event.56, 149 However, the existence, regulation, and function of RUNX1DEx6 has not
been characterized in AML.

1.7 Conclusion
Acute myeloid leukemia is a heterogeneous group of hematologic malignancies. With few
exceptions, outcomes for patients with this disease are suboptimal. We have outlined several
features of AML that can be used as prognostic and therapeutic guides. Despite newly approved
therapeutic agents, many patients remain ineligible for these drugs—mandating further drug
development via a deeper understanding of leukemogenic mechanisms.

To this end, we

discussed a role of the highly multifunctional protein hnRNP K in AML and reviewed the biology
of the critical transcription factor, RUNX1, in this disease. Furthermore, we discussed pre-mRNA
splicing biology and the aberrant splicing observed in AML and other myeloid malignancies. We
presented the role of hnRNP K in splicing, and finally, discussed alternative splicing of RUNX1.

1.8 Hypothesis and research goals
This dissertation begins with an investigation into the expression and clinical impact of
hnRNP K in AML. While haploinsufficiency of HNRNPK has been described, along with scarce
mutations in this gene, no studies have systematically evaluated hnRNP K expression in cases
of AML. In Chapter 3, we formally test the hypothesis that hnRNP K is an uncharacterized
oncogene in AML by developing and characterizing a mouse model of hnRNP K-overexpression.
In Chapter 4, we begin to evaluate a mechanism of the oncogenic functions of hnRNP K by
utilizing unbiased screening methods. In the fifth and final experimental chapter, we characterize
the interaction between hnRNP K and RUNX1 RNA in vitro and in vivo.
Our working hypothesis is that hnRNP K, when overexpressed, is an uncharacterized
oncogene in AML that functions in part through its post-transcriptional interactions with RUNX1.
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To this end, I endeavored to:
1. Evaluate the hnRNP K expression in AML and characterize its clinical impact
2. Describe the hematologic consequences of hnRNP K overexpression in vivo
3. Elucidate the molecular basis of the oncogenic function of hnRNP K
4. Examine the functional consequences of the hnRNP K-RUNX1 interaction

1.9 Significance
This work will provide great insight into the role of hnRNP K overexpression in myeloid biology
and leukemogenesis. By understanding the interaction between RUNX1 and hnRNP K, future
studies will be able to explore therapeutic opportunities to alter this interaction and thereby
dramatically improve outcomes for patients with hnRNP K-overexpressing AML.
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Chapter 2
hnRNP K is overexpressed in acute myeloid leukemia and is associated with inferior
outcomes
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2.1 Introduction
Acute myeloid leukemia (AML) encompasses a constellation of diseases characterized
by recurrent genetic and/or cytogenetic abnormalities. Outcomes for patients with AML have
historically been quite dismal. For example, in the 1970s, 5-year overall survival (OS) for patients
diagnosed with AML and treated at MD Anderson Cancer Center was a mere 13%.12 With
improvements in chemotherapeutic regimen composition and dosing, as well as supportive care,
this number improved to 49% in 2015.12

To further improve upon these outcomes, the

hematology community has expended incredible efforts to understand the driving events
underlying AML development such that better therapeutic options can be created, thereby
prolonging the quantity and quality of patient life. Indeed, many of the mutated proteins identified
in AML (FLT3, IDH1, IDH2, JAK2) can now be targeted with small molecular inhibitors that have
either been FDA-approved or are in late phases of clinical trials.33
In 2013, The Cancer Genome Atlas published a landmark study delineating the most
commonly mutated genes in de novo AML.32 This list of genes has been validated and expanded
upon by others.33, 34 Among these genes is HNRNPK, which encodes for the RNA-binding protein
heterogeneous nuclear ribonucleoprotein K (hnRNP K).32, 33 HNRNPK mutations were described
to occur in approximately 1% of AML patients in these studies.32-34 In addition to the small
proportion of patients with HNRNPK mutations, the mutations that were described did not cluster
in a single hotspot of the gene, nor did they aggregate in a portion of the gene encoding for a
single functional domain. This motivated us to evaluate our own patient population at MD
Anderson Cancer Center, where targeted exonic HNRNPK sequencing has been a routine
clinical test since 2016.156
HNRNPK resides on chromosome 9q21.32, which is specifically deleted in ~2% of
patients with AML, and leads to haploinsufficiency.35-37 Our group previously demonstrated that
decreased expression of HNRNPK causes myeloid malignancy in a mouse model, thus
confirming its role as a haploinsufficient tumor suppressor.53 This finding highlights that gene
13

dosage, perhaps independent of mutation status, may also contribute to AML development.
Therefore, we evaluated HNRNPK expression levels in AML patients.
To assess whether HNRNPK aberrations beyond genomic aberrations may be evident in
these patient populations, we evaluated RNA and protein expression and correlated these results
with patient outcomes. Taken together, our data demonstrate that hnRNP K is highly expressed
in a subset of patients with AML and these patients have inferior clinical outcomes compared to
patients with lower levels of hnRNP K.
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2.2 Materials and Methods
HNRNPK Sequencing: Genomic DNA was extracted from bone marrow specimens with an
Autopure extractor (Qiagen, Valencia, CA, USA). Libraries were prepared from genomic DNA
using hybridization capture-based enrichment of regions of interest. For HNRNPK, this included
exons 3-7 (amino acids 1-95) and 7-17 (amino acids 100-465). A next generation sequencing
platform was used to perform bidirectional paired-end sequencing to detect single nucleotide
variants (SNVs) and insertions or deletions up to 52 base pairs (Illumina Inc., San Diego, CA,
USA). GRCh37/hg19 was the genomic reference sequence used. Total sequencing coverage
depth was at least 250 reads. The lower limit of detection was 5% for clinical reporting.156

Fluorescence in situ hybridization (FISH) and Giemsa staining: Bone marrow cells harvested
from patients were treated with 0.1µg/mL colcemid for 30 minutes and resuspended in a
hypotonic solution for 30 minutes, after which Carnoy’s fixative solution (3:1 methanol:glacial
acetic acid) was added. Cells were then placed onto slides, and kept at 60°C overnight. The
next day, slides were placed in 0.05% trypsin-EDTA for 1 minute and 45 seconds, then
sequentially washed in isoton diluent and Gurr’s buffer (pH 6.8), Giemsa stained for 45 seconds,
and rinsed in water. G-banding was evaluated via microscopy. For FISH hybridization, slides
were aged and dehydrated in an ethanol gradient before denaturation took place at 73°C for 5
minutes followed by hybridization for 24 hours at 37°C. The RP11-19G1 probe was developed
to recognize chromosome 9p (control) and the HNRNPK probe (RP11-101L4) to the 9q21.32
locus. DAPI was used as a counterstain.

qRT-PCR: Bone marrow or peripheral blood samples were subjected to adequate red blood cell
lysis with BD Pharm Lyse lysing solution (BD Biosciences, San Jose, CA, USA) and RNA
extracted and purified using phenol/chloroform.157 Samples were treated with DNAse for 30
15

minutes at 37°C, and quantified using a NanoDrop spectrophotometer (ThermoFisher Scientific,
Waltham, MA, USA). 1µg of RNA was reverse transcribed using iScript (BioRad, Hercules, CA,
USA).

qRT-PCR was performed using iTaq Universal SYBR Green Supermix as per

manufacturer’s instructions (BioRad, Hercules, CA, USA) using an ABI StepOnePlus Real Time
PCR System. Expression of HNRNPK was evaluated using primers as follows: Forward: 5’
GCAGGAGGAATTATTGGGGTC 3’, Reverse: 5’ TGCACTCTACAACCCTATCGG 3’. Changes
in expression were determined by comparing HNRNPK expression to the housekeeping control
RPLP0. Primers for RPLP0 Forward: 5’ CCTTCTCCTTTGGGCTGGTCATCCA 3’ and reverse:
5’ CAGACACTGGCAACATTGCGGACAC 3’. Individual samples were assayed in triplicate.
Calculations were performed using the Pfaffl method comparing expression changes between
target genes and housekeeping control.158

Immunohistochemistry: Formalin-fixed paraffin-embedded bone marrow biopsies were
deparaffinized in xylene and rehydrated in an alcohol gradient. Antigen retrieval was performed
using 10mM sodium citrate and 0.05% Tween 20 (pH 6.0) in a steam chamber for 45 minutes.
Slides were incubated in 3% hydrogen peroxide/methanol solution to deactivate endogenous
peroxidases and subsequently incubated with anti-hnRNP K antibody (Abcam, Cambridge, MA,
USA, ab18195, 3C2, 1:3000 dilution) at 4°C overnight in a humidity chamber. Slides were
washed with 0.1% Tween-PBS before biotinylated secondary antibody was added at room
temperature for 30 minutes. Antibody-protein interactions were visualized with Vectastain Elite
ABC and DAB peroxidase substrate kits (Vector Laboratories, Burlingame, CA, USA). Nuclear
fast red was used as a counterstain.

Reverse phase protein array: Methodology is fully described elsewhere.159-161 Briefly, bone
marrow protein samples were printed in replicate in serial dilutions onto slides along with controls
for normalization and expression. A panel of 230 strictly validated primary antibodies was used
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to probe the slides, and a stable dye is precipitated after addition of a secondary antibody. A
complete description of the antibodies is included elsewhere.161 The primary antibody against
hnRNP K was from Santa Cruz Biotechnology (Dallas, TX, USA, sc-28380, D6). Stained slides
were analyzed with Microvigene software (Version 3.4, Vigene Tech, Carlisle, MA, USA). Data
is publicly available at www.leukemiaatlas.org.162 Acute promyelocytic (FAB M3) cases were
excluded.

Data normalization and processing: SuperCurve algorithms163 was used to generate a single
expression value for each sample from the series of dilutions. The average expression level of
each replicate sample was used for downstream analysis.

Topographical normalization

procedures164 and loading controls165 were included. Protein expression levels were described
as relative to the median of CD34+ bone marrow specimens from healthy donors.

Statistical analyses: Overexpression of hnRNP K protein was defined as any expression greater
than or equal to one standard deviation above the median expression for normal, healthy CD34+
bone marrow. Correlations between these expression levels and clinical features were assessed
using Wilcoxon rank-sum test. Survival curves were generated using the Kaplan-Meier method.
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2.3 Results
HNRNPK mutations are rare in AML
Since implementation of the 81-gene targeted-sequencing panel that tests for mutations
in leukemia-associated genes, samples from 238 unique AML patients have been sequenced at
MD Anderson. Of these patients, HNRNPK mutations were identified in seven individuals (2.9%
of cases). A schematic of these mutations and their location within the coding sequence are
depicted in Figure 2. These mutations were not clustered in a single region of the gene, and
were distributed throughout regions encoding for several functional domains of the hnRNP K
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Figure 2. HNRNPK mutations in AML at MD Anderson. Schematic of hnRNP K with each
domain indicated. Numbers above the domains correspond to the amino acid residue that limit
each domain. Mutations identified in AML patients at MD Anderson are depicted on the domain
diagram. Each mutation was identified once within our patient cohort. Diagram is not to scale.

Splicing factor mutations are overrepresented in cases with mutant HNRNPK
Table 1 includes the cytogenetics and co-occurring mutations for each case with an
identified HNRNPK mutation. Due to the very small sample size, it is challenging to draw
definitive conclusions about enrichment of co-occurring mutations or cytogenetic abnormalities.
However, 5/7 (71.4%) patients with an HNRNPK mutation also had a co-occurring mutation in a
splicing factor gene, such as U2AF1, SRSF2, or SF3B1. This is more than would be expected,
since the incidence of such mutations in AML ranges from 4-6% for U2AF1, 1-12% for SRSF2,
and 1-4% for SF3B1, and these mutations are virtually always mutually exclusive of one
another.32-34
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HNRNPK
mutation

Amino acid
change

Other mutations

Cytogenetics

26C>T

T9I

IDH2 R140Q
NPM1 W288fs
SRSF2 P95H

46,XY

166G>A

A56T

KRAS G12C
NRAS Q61K
RUNX1 R166Q
SF3B1 K666E

46,XX,t(3;12)(q26.2;p13),del(7)(q22q36)[18]/46,idem[cp2]

457del

Q153fs

FLT3 D835H
TP53 R248G
RUNX1 D332fs

47,XY,+8[12]/48,idem,+9[8]

G197A

KRAS G12V
NRAS G12D
U2AF1 S34F
WT1 H465L

46,XY

856C>T

R286C

DDX41 R525H
DDX41 R159*
SRSF2 P95H

46,XY,del(2)(p16)[1]/46,XY,t(8;19)(p21;q13.3)[1]/46,XY[18]

914G>T

R305L

TP53 A119G
FBXW7 R505C
GATA2 S24*

43~45,Y,-X,der1(t1;5)(q21;q13),-2,-3,del(4)(q22),
der(5)del(5)(p14)t(1;5),t(6;7)(p23;q11.2),del(7)(p15),-9,-16,
add(21)(q22),+2~5mar[cp20]

Y333*

DNMT3A R887fs
NPM1 W288fs
NRAS G12A
SF3B1 K666N

46,XY

590G>C

998dupA

Table 1. Co-occurring mutations and cytogenetic features of AML cases with mutant
HNRNPK. Table lists the mutations observed in HNRNPK, the resultant amino acid change in
hnRNP K, co-occurring mutations detected at diagnosis, and cytogenetic features. Mutations in
genes encoding splicing factors are indicated in red.

HNRNPK RNA is elevated in a subset of AML patients
In the context of our previous work demonstrating that low expression of hnRNP K could
result in myeloid malignancy, we next sought to evaluate whether expression of hnRNP K was
altered in patients with AML without 9q21.32 deletions. We evaluated expression of HNRNPK
RNA by qRT-PCR on bone marrow samples from patients with AML compared to CD34+ cells
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from healthy donor bone marrow (Figure 3A).

While the difference in median HNRNPK

expression between AML patients and healthy donors was not statistically significant (p=0.16), a
subset of patients (5/18; 27.8%) had demonstrably higher HNRNPK expression than healthy
controls. When analyzed separately, this difference was statistically significant (p=0.02, Figure
3B). To confirm these data, we performed qRT-PCR on a separate cohort of AML bone marrow
samples from patients with cytogenetically normal disease from a different institution (Centro
Nacional de Investigaciones Oncológicas [CNIO]; Madrid, Spain; Figure 3C). Again, a subset of
patients (3/15; 20%) had clearly elevated HNRNPK expression even though the difference in
median HNRNPK expression between groups did not differ.
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Figure 3. HNRNPK RNA is overexpressed in a subset of AML. qRT-PCR for HNRNPK
expression in patients with AML from MD Anderson Cancer Center (A-B) or CNIO (C). Each
point represents an individual patient sample. Lines are drawn at the median with tails extending
to the interquartile range. Each dot indicates an individual patient sample.

hnRNP K protein is elevated in a subset of AML
To evaluate whether this increase in RNA expression corresponded to an increase in
hnRNP K protein expression, we analyzed a reverse phase protein array (RPPA) from a different
cohort of patients previously treated at our institution. This compared hnRNP K expression in
bone marrow from patients with protein expression in CD34+ bone marrow cells from healthy
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donors.

Strikingly, median hnRNP K expression was significantly higher in AML samples

compared with healthy donors (p=0.0056, Figure 4A).

We confirmed this altered protein

expression using hnRNP K immunohistochemistry (IHC) from samples used in the RPPA (Figure
4B). Indeed, cases that were deemed to have high hnRNP K expression by RPPA stained
strongly for hnRNP K by IHC. Likewise, samples with low expression of hnRNP K by RPPA had

A

Relative hnRNP K protein expression

only weak hnRNP K staining by IHC.

B
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3
2

hnRNP K OE AML
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-3
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Figure 4. hnRNP K protein is overexpressed in a subset of AML. A. Normalized hnRNP K
protein expression data from RPPA. Line is drawn at median expression with bars reaching
within one interquartile region. Each dot represents a sample from an individual patient. B.
hnRNP K IHC on representative samples from the RPPA dataset represented in panel A.

Elevated hnRNP K expression is associated with inferior clinical outcomes in AML
To determine whether increased hnRNP K expression was associated with altered clinical
outcomes, we performed Kaplan-Meier analysis on patients stratified according to hnRNP K
expression by RPPA. For these analyses, patients with hnRNP K expression greater than or
equal to one standard deviation above the median of healthy control bone marrow were
considered to have high hnRNP K expression. With this cutoff, 45 patients (22%) overexpressed
hnRNP K, and 160 had normal or low hnRNP K expression. Patients with elevated hnRNP K
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had statistically significant decreases in both remission duration (HR 2.1; 95% CI 1.2-3.6; Figure
5A) and overall survival (24.3 months versus 48.7 months; HR 1.9; 95% CI 1.3-2.7; Figure 5B).
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Figure 5. hnRNP K overexpression is associated with inferior outcomes. Kaplan-Meier
analysis of remission duration (A) or overall survival (B) in patients with AML stratified according
to hnRNP K protein expression. Red lines indicate patients with hnRNP K overexpression
(greater than one standard deviation above the median of healthy controls). Blue lines indicate
the remainder of the group with normal/low hnRNP K expression.

Elevated hnRNP K expression is enriched in immature AML subtypes
To evaluate whether hnRNP K overexpression was enriched in AML of particular
morphology, we evaluated hnRNP K protein expression in cases according to French-AmericanBritish (FAB) classification. Median hnRNP K expression was higher in M0 and M1 cases
compared with M2, M4, or M5 (Figure 6).
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expression data as assessed by RPPA and categorized according to FAB subtype. Lines are
drawn at the median with tails reaching the interquartile range.

Elevated hnRNP K expression is correlated with mutations in NPM1 and FLT3
To evaluate the specific context in which hnRNP K is highly expressed in AML, we sought
to determine whether high hnRNP K expression co-occurred with common mutations. Mutations
in FLT3 in the absence of a concomitant NPM1 mutation did not exhibit an appreciable difference
in hnRNP K expression (Figure 7). Interestingly, an NPM1 mutation in the absence of FLT3
mutation did have a statistically significant increase in hnRNP K expression. In line with this
observation, cases with both NPM1 and FLT3 mutations also had a statistically significant
increase in hnRNP K expression (Figure 7). Mutations in TP53, NRAS, KRAS, RUNX1, and
IDH1/2 did not correlate with changes in hnRNP K expression (data not shown).
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Figure 7. hnRNP K overexpression is enriched in NPM1 mutant cases. Normalized hnRNP
K expression stratified according to mutational status of NPM1 and FLT3. Lines are drawn at
the median and tails reach to within one interquartile range.

High hnRNP K expression in the context of NPM1 mutations is associated with inferior outcomes
To assess the impact of hnRNP K expression in the context of these mutations, we
performed Kaplan-Meier analysis on patients based on hnRNP K status. Patients with any
mutation in NPM1 who also had greater than median hnRNP K expression had a statistically
significant decrease in overall survival (p=0.022, Figure 8A). Since NPM1 mutations in the
context of wildtype FLT3 have a relatively fair prognosis27, we also specifically evaluated this
subset of patients.

Patients harboring NPM1MutFLT3WT and higher than median hnRNP K

expression had inferior overall survival, though this was not statistically significant, likely due to
limited sample size (Figure 8B). Given these findings, evaluating hnRNP K expression in this
specific subset of patients may offer prognostic guidance for this otherwise favorable subgroup.
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Figure 8. hnRNP K overexpression in the context of NPM1 mutations is associated with
decreased overall survival. Kaplan-Meier analyses of overall survival of AML patients with
mutant NPM1 (A) or mutant NPM1 and wildtype FLT3 (B) stratified according to hnRNP K
expression status. High expressors are shown in red.

The HNRNPK locus is amplified in a subset of AML and corresponds with increased hnRNP K
protein.
To understand a possible mechanism of this hnRNP K overexpression, we designed a
fluorescence in situ hybridization (FISH) probe that hybridizes to the HNRNPK locus.

As

expected, when we analyzed AML cases harboring chromosome 9q deletions, we only observed
one copy of HNRNPK that was detectable by FISH (Figure 9A). Strikingly, we found numerous
AML cases not harboring del(9q) had an extra copy of the HNRNPK locus (Figure 9A). Critically,
when we performed IHC on samples with extra copies of the HNRNPK locus, the protein product,
hnRNP K, was highly abundant (Figure 9B).

Therefore, one mechanism of hnRNP K

overexpression may be additional copies of the HNRNPK locus.
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hnRNP K

Figure 9. HNRNPK locus is duplicated in a subset of AML. A. (Left) Metaphase FISH using
HNRNPK specific probe (red) and a control 9p probe (green). Other images represent nuclei of
interphase cells from a healthy human donor, AML with del(9q), or diploid AML. Cells were
probed with HNRNPK (red) or control 9p probe (green) and counterstained with DAPI (blue). B.
hnRNP K IHC on healthy human bone marrow (left) or AML bone marrow with three copies of
HNRNPK as identified by FISH.

Additional HNRNPK loci are present as small supernumerary marker chromosomes
Given the presence of additional copies of HNRNPK in several AML cases, and the
propensity of translocations to occur in hematologic malignancies, we wanted to examine
whether HNRNPK may partake in a translocation event. When we performed FISH on AML
samples alongside Giemsa staining, we were unable to locate a consistent chromosome with
which HNRNPK was associated. Instead, HNRNPK appeared in locations that did not stain with
Giemsa, but only with DAPI—meeting the criteria of a small supernumerary marker chromosome
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(sSMC; Figure 10).166 This indicates that HNRNPK duplications do not occur in the context of
translocations, but are present as sSMCs.

A

B
9p probe
HNRNP K

C

Figure 10. Additional HNRNPK loci exist as small supernumerary marker chromosomes.
AML patient bone marrow metaphase subjected to (A) FISH with HNRNPK shown in red and a
control 9p probe in green or (B) Giemsa staining. Red circles are drawn around chromosome 9.
Blue arrow indicates presence of an additional HNRNPK locus. C.

Magnified view of the

additional HNRNPK locus (left) and the two chromosomes 9 (right).
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2.4 Discussion
These studies elucidate that hnRNP K is overexpressed in a subset of patients with AML
at both the RNA and protein level. Importantly, the overexpressed hnRNP K is unlikely to be
mutated, since mutations in HNRNPK are rare events—occurring in less than 3% of patients,
and the overexpression occurs in a much larger subset of patients (~20%) (Figures 3, 4). This
corroborates previous reports of HNRNPK mutations, where incidences mingled near a mere
1%.32-34
The HNRNPK mutations we found in AML patients at MD Anderson were largely unique.
A single AML patient has been described as having an A56G mutation, similar to the A56T
mutation we identified.34 Of interest, the Y333* mutation has been described in a patient with
AML33, but has also been observed in a patient with Au-Kline syndrome—a multiple malformation
syndrome resulting from germline mutations or deletions of HNRNPK.38, 167 Perhaps then, it is
not surprising that this mutation has been suggested to undergo nonsense-mediated decay, and
therefore mimic HNRNPK haploinsufficiency.38 However, the functional consequences of this
mutation and the others we identified have not been formally characterized. Despite the rarity of
these mutations, future work evaluating their functional consequences may be an impactful
means to more thoroughly understand the biologic role of hnRNP K in multiple tissue types.
Despite having a very small cohort, we noticed that HNRNPK mutations in AML appeared
to coexist with splicing factor mutations (SRSF2, U2AF1, or SF3B1). This is an intriguing
observation since mutations in these genes are only estimated to occur in approximately 15% of
AML.32-34, 168 As hnRNP K has itself been implicated in splicing56, 149, 154, 169 (see Chapters 4-5),
future studies investigating these relationships would be of particular interest.
Data presented in this chapter indicate that HNRNPK transcript is elevated in a subset of
AML patients (Figure 3). This observation was mirrored in a cohort of patients from CNIO in
Spain (Figure 3C). While both patient cohorts for qRT-PCR analyses were relatively small,
similar observations between these samples from completely separate institutions bolsters the
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conclusion that HNRNPK is overexpressed in ~20% of AML. These findings were greatly
substantiated by the observation that hnRNP K protein was also elevated in AML samples
compared to healthy controls (Figure 4). While some may therefore conclude that the majority
of AML cases “overexpress” hnRNP K (as one interpretation of the term “overexpression” is
anything above “normal expression”170), we chose to be more cautious in our definition of this
admittedly subjective term. As the median of hnRNP K expression in AML was already greater
than that of healthy controls, we chose to increase our threshold to one standard deviation above
this measure. With this cutoff, we identified cases with substantially increased hnRNP K, a
finding that was further validated by hnRNP K IHC (Figure 4B). Therefore, we used this as the
definition of hnRNP K overexpression.
When AML cases were stratified according to hnRNP K overexpression, we observed
statistically significant decreases in remission duration and overall survival (Figure 5). It is
relevant to note that the RPPA data, and therefore these cutoffs, were generated from a cohort
of patients treated prior to 2015.162 Almost all of these patients were treated with similar
chemotherapy-based regimens, devoid of hypomethylating agents, targeted small molecules,
immunotherapies (including antibodies), or cellular therapies. It is thus possible that differences
in these clinical outcomes associated with hnRNP K expression are more reflective of the
underlying disease biology, not merely an artifact of response to more sophisticated therapeutic
agents. On the other hand, with the widespread use of these agents, hnRNP K overexpression
as a single stratification criterion may no longer be sufficient to separate outcomes. Prospective
studies would be relevant to further understand the impact of hnRNP K overexpression on patient
outcomes in the context of the most up to date therapeutic options.
We found that AML cases with more immature phenotypes by FAB subclass (M0 or M1)
had increased hnRNP K expression compared to more mature cases (Figure 6). This is only
partly consistent with microarray data in healthy human hematopoiesis, where HNRNPK
expression is relatively high in hematopoietic stem cell subsets and decreases slightly in cells
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that are fully committed to monocytic or megakaryocytic differentiation.171 In our data, cases of
M5 (monocytic) and M7 (megakaryocytic) AML had lower hnRNP K levels than more
undifferentiated cases (M0 and M1). Unlike the observations in healthy hematopoiesis, where
HNRNPK expression did not substantially decrease early in differentiation171, we observed that
M2 and M4(eos) cases had a relatively steep drop off in hnRNP K expression.
To more specifically identify subpopulations of patients with elevated hnRNP K
expression, we evaluated hnRNP K expression in cases with mutated NPM1 and/or FLT3.
hnRNP K expression did appear to be increased in the setting of NPM1 and FLT3 mutations
(Figure 7). Patients harboring mutated NPM1 with concomitant hnRNP K overexpression had
decreased overall survival compared to those with lower hnRNP K expression.

This is

particularly important in the subgroup of patients with mutated NPM1 in the context of wildtype
FLT3, as such patients are normally considered to have a favorable prognosis.27 Strikingly, these
patients had dramatically worse overall survival when hnRNP K was overexpressed. Future
studies evaluating the interaction between mutant NPM1 and hnRNP K overexpression are
certainly warranted.
The mechanism of the hnRNP K overexpression described in this chapter remains
unclear; however, we did identify the presence of the HNRNPK locus as a small supernumerary
marker chromosome (sSMC) that corresponded to high hnRNP K protein expression by IHC.
When so-called marker chromosomes occur in AML, these can predict adverse prognosis172;
however, these are identified in routine cytogenetic testing. The sSMCs we identified are only
detected by FISH, and would be missed in routine cytogenetic testing. Therefore, the FISH probe
we developed could have clinical potential as it would identify these sSMCs and also readily
identify patients with AML harboring del(9q) encompassing this locus. Prospective studies with
this probe may be of clinical utility. In addition, future investigations into the genomic contents of
these sSMCs would be of great interest, as it may provide insight into the endogenous regulation
of HNRNPK expression in disease states.
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Small clinical studies have correlated high hnRNP K expression with inferior clinical
course in several solid tumor types, including melanoma, breast, nasopharyngeal, pancreatic,
hepatocellular, colorectal, bladder, and prostate cancers.75-82 Importantly, we have recently
identified that overexpression of hnRNP K can have oncogenic activity in the setting of B-cell
lymphoma.83 Thus, it is reasonable to hypothesize that high expression of hnRNP K may be
pathogenic in the setting of myeloid malignancy. Chapter 3 will address this hypothesis in detail.

31

Chapter 3
hnRNP K overexpression drives myeloproliferative disease in murine models
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3.1 Introduction
In Chapter 2, we determined that hnRNP K was overexpressed in a subset of patients
with AML, and this overexpression was associated with inferior clinical outcomes.

These

observations alluded to the notion that hnRNP K may act as an oncogene when overexpressed
in AML. While limited clinical studies in solid tumors have seen hnRNP K overexpression75-82,
data regarding a role for hnRNP K in hematologic malignancies is sparse.
AML has been described as a disease arising from aberrations in hematopoietic stem
and progenitor cells.173-175 Thus, an in vivo model used to evaluate an oncogenic role for hnRNP
K should harbor hnRNP K overexpression in these immature cells. We approached generating
a mouse model of such using retroviral transduction of Hnrnpk into murine hematopoietic stem
and progenitor cells followed by transplantation into recipient mice.
Throughout a portion of mammalian development in utero, the fetal liver is the primary
site of hematopoiesis. In mice, beginning at embryonic day 11.5 (E11.5), hematopoietic stem
cells (HSCs) begin to seed the fetal liver, and by E12.5, the fetal liver becomes the predominant
site of HSC expansion.176, 177 Here, HSC number increases between E13.5-16.5, then declines
steadily until HSCs shift to bone marrow at E17.5.178 Throughout this time, progenitor cells are
also abundant in the fetal liver.179 Murine fetal liver cells (FLCs) from E13.5-16.5 therefore serve
as a rich source of hematopoietic stem and progenitor cells. Furthermore, FLCs can be virally
transduced to stably alter gene expression.180, 181 Transplantation of these genetically altered
FLCs into recipient mice is a rapid and efficient way to restrict expression of the gene of interest
to the hematopoietic system.180, 181
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3.2 Materials and Methods
Plasmids: Retroviruses were made in an MSCV backbone and were modified from those
described previously.180 MSCV-AML1/ETO-IRES-GFP plasmid was obtained from Addgene
(plasmid #60832).180 The green fluorescent protein (GFP) coding sequence was replaced with
firefly luciferase ORF obtained from a luciferase-pcDNA plasmid (Addgene plasmid #18964).182
For generation of empty vectors, AML1/ETO was excised using EcoRI and BamH1 and plasmid
re-ligated.

To generate MSCV-HNRNPK-IRES-GFP and MSCV-HNRNPK-IRES-Luciferase,

AML1/ETO was replaced with HNRNPK that was PCR amplified from 293T cells.

Retroviral production: HEK293T cells at 50% confluency in T75 flasks were transfected with 4 µg
of transfer vector (MSCV-(HNRNPK)-IRES-GFP/Luciferase) and 4 µg of pCL-Eco packaging
vector (Addgene plasmid #12371)183 with 12 µL of JetPrime DNA transfection reagent (Polyplus
Transfection, New York, NY, USA). Fresh stem cell medium without cytokines (see below) was
supplied after 4-8 hours and cells were incubated at 32°C for 48-72 hours. High-titer retroviral
supernatant was collected and passed through a 0.45 µm filter.

Fetal liver cell (FLC) isolation: The University of Texas MD Anderson Cancer Center Animal Care
and Use Committee approved all mouse experiments performed in these studies under protocols
0000787-RN01 and 0000787-RN02. Pregnant wildtype CD45.2+ C57/Bl6 females were
euthanized by exposure to CO2 at day 13.5-16.5 of gestation. Fetal livers were sterilely dissected
and gently disrupted on a 70 µm filter to obtain a single-cell suspension. The collected cells were
briefly subjected to a red blood cell (RBC) lysis with BD Pharm Lyse buffer (BD Biosciences, San
Jose, CA, USA). After RBC lysis, cells were resuspended in stem cell medium at ~3x106 cells/mL
and incubated at 37°C overnight prior to retroviral transduction. Stem cell medium contained 37%
DMEM (Corning, Corning, NY, USA), 37% Iscove’s modified Dulbecco’s Medium (Corning,
Corning, NY, USA), 20% fetal bovine serum, 2% L-glutamine (200mM; Corning, Corning, NY,
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USA), 100 U/mL penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA), 5x10-5 M 2mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA), recombinant murine interleukin-3 (IL-3;
0.2 ng/mL), interleukin-6 (IL-6; 2 ng/mL), and stem cell factor (SCF; 20 ng/mL; all cytokines from
Stem Cell Technologies, Vancouver, Canada).

FLC transduction and sorting: Approximately 5x106 FLCs were resuspended in 2 mL of high-titer
retroviral supernatant supplemented with 12 µg/mL polybrene and cytokines (IL-3; 0.2 ng/mL, IL6 2 ng/mL, and SCF 20 ng/mL). Plates were then spun at 600xg for 90 minutes at room
temperature and incubated at 32°C for 48-72 hours. After transduction, cells infected with GFPcontaining constructs were sorted for GFP positivity using the MoFlo Astrios cell sorter (Beckman
Coulter, Brea, CA, USA) at the MD Anderson Cancer Center North Campus Flow Cytometry
Core Facility.

qRT-PCR: Bone marrow and spleen samples were subjected to adequate red blood cell lysis
with BD Pharm Lyse lysing solution (BD Biosciences, San Jose, CA, USA). For all samples,
RNA was extracted and purified using phenol/chloroform.157 Samples were treated with DNAse
for 30 minutes at 37°C, and quantified using a NanoDrop spectrophotometer (ThermoFisher
Scientific, Waltham, MA, USA). 1µg of RNA was reverse transcribed using iScript (BioRad,
Hercules, CA, USA). qRT-PCR was performed using iTaq Universal SYBR Green Supermix as
per manufacturer’s instructions (BioRad, Hercules, CA, USA) using an ABI StepOnePlus Real
Time PCR System. Changes in expression were determined by comparing expression to the
housekeeping control Rplp0. Expression of Hnrnpk was evaluated using primers as follows:
Forward

(sp240):

5’-GAAGATATGGAAGAGGAGCAAGCC-3’,

CAAGGTAGGGATGATTTTCTTC-3’
CCCTGAAGTGCTCGACATCA-3’,

(sp240-242),
Rplp0

Reverse:

Rplp0

Reverse

(sp242):

Forward:

5’5’-

5’-TGCGGACACCCTCCAGAA-3’.
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Individual samples were assayed in triplicate, and calculations were performed using the Pfaffl
method comparing expression changes between target genes and housekeeping control.158

Western blotting: Cells were homogenized in NP40 lysis buffer containing protease and
phosphatase inhibitors (Millipore Sigma, Burlington, MA, USA). Soluble proteins were boiled in
Laemmli buffer, resolved on a 10% SDS-PAGE gel, and transferred to a PVDF membrane.
Membranes were blocked with 5% milk for one hour at room temperature and incubated with
primary antibody at 4°C overnight while rocking. Primary antibodies were hnRNP K (3C2,
1:1000, Abcam, Cambridge, MA, USA) and b-actin (AC-15, 1:2000, Santa Cruz, Biotechnology,
Dallas, TX, USA). Membranes were incubated with secondary antibody and antibody-protein
interactions were visualized using enhanced chemiluminescence (GE Healthcare, Chicago, IL,
USA) or BCIP/NBT color development substrate (VWR International, Radnor, PA, USA).

Colony formation assay: GFP sorted FLCs were cultured in quadruplicate wells of a 12-well plate
in methylcellulose medium with cytokines IL-3, IL-6, erythropoietin, and stem cell factor
(Methocult GF M3434, StemCell Technologies, Vancouver, Canada). 50,000 cells were plated
per well and colonies were counted after 7 days. Colonies were gently disrupted in PBS and
cells counted manually with a hematocytometer using trypan blue dye exclusion, or subjected to
cytospin or flow cytometry. Cytospins were stained with Wright-Giemsa.

Flow cytometry: Cells were harvested and washed with PBS supplemented with 5% bovine
serum albumin (BSA; Sigma Aldrich, St. Louis, MO, USA). Prior to antibody staining, cells were
treated with murine Fc block (TruStain FcX, BioLegend, San Diego, CA, USA) at room
temperature for 15 minutes. Cells were incubated with fluorescently labeled antibodies in the
dark at room temperature for 30 minutes-1 hour. Antibodies used: Gr1 [RB6-8C5], CD11b
[M1/70;], CD117 [2B8], CD45 [30F11] (all from BD Biosciences, East Rutherford, NJ, USA), and
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Sca-1 [D7; eBioscience, San Diego, CA, USA]. Flow cytometry was performed in the MDACC
North Campus Flow Cytometry Core Facility using a Gallios flow cytometer (Beckman Coulter,
Brea, CA, USA). Data was analyzed using FlowJo Software (Beckton Dickinson, Franklin Lakes,
NJ, USA).

FLC transplantation: NOD-scid-IL2R-gamma (NSG) mice were purchased from the MDACC
Department of Experimental Radiation Oncology. NSG mice were sub-lethally irradiated with 2.5
Gy administered as a single dose 4-24 hours prior to transplantation. At least 40,000 (up to
1x106) cells suspended in sterile PBS were injected into the retroorbital sinus of mice under
isoflurane-induced anesthesia. Engraftment was evaluated using in vivo bioluminescent imaging
(see below) or flow cytometry analysis of peripheral blood. In the latter case, blood was collected
from the retro-orbital sinus of isoflurane-anesthetized mice on a monthly basis.

In vivo bioluminescent imaging: Mice were injected intraperitoneally with D-luciferin, anesthetized
with isoflurane, and imaged using an IVIS system (Xenogen/Caliper Life Sciences, Alameda, CA,
USA). Imaging was performed on a weekly basis beginning one week after transplantation to
monitor and ensure engraftment.

Peripheral blood analysis: Blood was collected from the retro-orbital sinus of isofluraneanesthetized mice into EDTA-coated tubes. Complete blood count analysis was performed with
an ABX Pentra analyzer (Horiba, Kyoto, Japan). Peripheral blood smears were stained with
Wright-Giemsa.

Tissue procurement: At time of necropsy, spleen, liver, and sternum were collected from each
mouse. Tissues were fixed in 10% neutral-buffered formalin and processed by the Research
Histopathology Facility at MD Anderson Cancer Center where paraffin-embedded blocks were
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made and sectioned. Each section was stained with standard hematoxylin/eosin staining. Cells
were also collected from femurs and remaining spleen in a single cell suspension, subjected to
a gentle RBC lysis, and processed for western blotting or qRT-PCR as described above.

Immunohistochemistry: Formalin-fixed paraffin-embedded tissues were deparaffinized in xylene
and rehydrated in an alcohol gradient. Antigen retrieval was performed using 10mM sodium
citrate and 0.05% Tween 20 (pH 6.0) in a steam chamber for 45 minutes. Slides were incubated
in 3% hydrogen peroxide/methanol solution to deactivate endogenous peroxidases. Incubation
with primary antibody was at 4°C overnight in a humidity chamber. Slides were washed with
0.1% Tween-PBS before biotinylated secondary antibody was added at room temperature for 30
minutes. Antibody-protein interactions were visualized with Vectastain Elite ABC and DAB
peroxidase substrate kits (Vector Laboratories, Burlingame, CA, USA). For all antibodies, DAB
time was 3 minutes. Nuclear fast red was used as a counterstain. Antibodies used for IHC are
included in Table 2.

Antibody
Clone
Secondary antibody
Vendor
Dilution
hnRNP K
3C2
mouse
Abcam
1:3000
CD34
MEC14.7
rat
ThermoFisher 1:100
CD117
2B8
rat
ThermoFisher 1:100
CD3
SP162
rabbit
Abcam
1:150
MPO polyclonal; ab9535
rabbit
Abcam
1:100
CD14
4B4F12
mouse
Abcam
1:100
Table 2. Antibodies used for IHC. Antibodies used for immunohistochemistry. With the
exception of MPO, antibodies were monoclonal; therefore, the clone is listed in lieu of a catalog
number.
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Survival analysis: Kaplan-Meier curves were generated using Prism software (GraphPad
Software, San Diego, CA). Time between transplantation of FLCs and death or veterinarianmandated euthanasia was used for analyses.
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3.3 Results
hnRNP K can be overexpressed in murine FLCs
To evaluate whether the FLC system was suitable for modeling hnRNP Koverexpression, we first infected FLCs with an hnRNP K-overexpression construct. Compared
to empty vector controls, these cells exhibited clear hnRNP K overexpression at both the RNA
and protein levels (Figure 11). This indicated that FLCs were capable of overexpressing hnRNP
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hnRNP K
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Figure 11. FLCs can overexpress hnRNP K. A. Bar graph of Hnrnpk qRT-PCR results,
normalized to Rplp0, in FLCs infected with an hnRNP K-overexpression vector (red) or empty
vector control (black). B. Representative western blot of FLCs infected with either hnRNP Koverexpression vector or empty GFP control. Cells were infected 48 hours prior to harvest.

hnRNP K overexpression results in altered colony forming potential
To evaluate whether overexpression of hnRNP K had a biologic effect on FLCs, we
performed colony formation assays. These assays can be used to assess self-renewal capacity
and differentiation potential of cells.184

When placed in colony formation assays, FLCs
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overexpressing hnRNP K formed more colonies than empty vector controls (Figure 12A). Of
note, colonies from hnRNP K-overexpressing FLCs were also visibly larger than empty vector
controls (Figure 12B), suggesting that hnRNP K-overexpression provides a proliferative
advantage to these cells.
A

*

B

Empty GFP

HNRNPK GFP

Figure 12. hnRNP K overexpression increases colony formation potential of FLCs. A. Bar
graph representing number of colonies formed per well in FLCs overexpressing hnRNP K (red)
or empty vector controls (black). B. Representative brightfield image of colonies from panel A.

hnRNP K overexpression alters colony phenotype
Given the increase in colony formation in hnRNP K-overexpressing cells, we sought to
examine the properties of the colonies that formed. Morphologic differences were observable in
Wright-Giemsa stained cytospins from colonies arising from hnRNP K-overexpressing cells
compared to empty vector controls (Figure 13A). In particular, cells from empty vector controls
appeared relatively uniform, while colonies overexpressing hnRNP K were more varied in cell
size and morphologic features. To evaluate these differences in a more definitive manner, we
examined cell surface marker expression by flow cytometry. These experiments revealed that
hnRNP K-overexpressing colonies had fewer mature myeloid cells (CD11b+Gr1+) compared to
controls (Figure 13B).

Consistent with this lack of mature myeloid cells, hnRNP K-

overexpressing colonies were enriched in immature c-kit+Sca1+ cells (Figure 13C).

As

hematopoietic stem cells differentiate, c-kit and Sca1 expression is downregulated.185-188 Thus,
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these data suggest that hnRNP K-overexpression results in maintenance of a stem-like
phenotype, leading to decreased percentage of mature myeloid cells, and an increase in colony
formation and self-renewal capacity. This could also represent a differentiation block, which is a
phenomenon often observed when leukemic cells are placed into colony formation assays.189
A

Empty vector

HNRNPK OE
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Hnrnpk OE
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Figure 13. hnRNP K-overexpressing colonies have altered immunophenotypes. A. WrightGiemsa stain of cytospins from representative colonies.

B.

Dot plot of Gr1 and CD11b

expression from representative colonies. Inset numbers indicate the percentage of cells that
were Gr1+ and CD11b+. C. Dot plot of Sca1 and c-kit expression from representative colonies.
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Inset numbers indicate the percentage of cells that were Sca1+ckit+. Flow cytometry data is
gated on CD45+ cells.

hnRNP K-overexpressing FLCs engraft in recipient mice
Since colony formation assays indicated that hnRNP K-overexpression altered the
differentiation and self-renewal properties of FLCs, we next asked whether this would translate
to a similar phenotype in vivo. Thus, we injected luciferase-containing FLCs intravenously into
sub-lethally irradiated NSG mice.

Serial in vivo imaging revealed luciferase activity in

hematopoietic tissues (bone marrow and spleen) of transplanted mice (Figure 14A), indicating
successful engraftment. Interestingly, recipients of hnRNP K-overexpressing FLCs frequently
had faster engraftment—a finding consistent with the increase in colony formation seen in Figure
13.
Since luciferase-containing FLCs could be successfully transplanted into NSG mice
regardless of hnRNP K expression, we next transplanted FLCs transduced with GFP-containing
constructs. The presence of GFP allowed us to sort and inject only cells that had successfully
been infected with the viral constructs, thus ensuring a more homogeneous population. Indeed,
mice injected with GFP-containing FLCs had measurable GFP positivity in peripheral blood that
was stable over time (Figure 14B).
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Figure 14. hnRNP K-overexpressing FLCs engraft in recipient NSG mice. A. In vivo
bioluminescent imaging of representative mice injected with either empty-Luciferase FLCs (left)
or hnRNP K-overexpressing-Luciferase FLCs (right). Images are from one representative mouse
from each group at matching timepoints over the course of 6 weeks. B. Bar graphs of GFP
positive cells in peripheral blood from mice injected with either empty-GFP FLCs (black) or
hnRNP K-overexpressing-GFP FLCs (red).

hnRNP K overexpression is maintained in vivo
To ensure that the transplanted FLCs maintained hnRNP K-overexpression as intended,
we assessed cells from spleen and bone marrow of recipient mice.

qRT-PCR revealed

consistently increased Hnrnpk expression in mice receiving hnRNP K-overexpressing FLCs
compared to empty vector controls (Figure 15A). Increased hnRNP K expression was also seen
at the protein level in spleen (Figure 15B). These findings support the notion that hnRNP Koverexpressing FLCs can engraft in recipient mice and be maintained in an in vivo setting.
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Figure 15. hnRNP K overexpression is maintained in vivo. A. Hnrnpk qRT-PCR, normalized
to Rplp0, from spleen and bone marrow of mice transplanted with empty vector FLCs or hnRNP
K-overexpressing FLCs (n=4). B. Western blot from spleens of representative mice. Each lane
is an individual animal. All samples were collected 4 weeks after transplant.

Recipients of hnRNP K-overexpressing FLCs have a survival disadvantage
Our data have shown that hnRNP K-overexpressing FLCs engraft in recipient mice and
maintain elevated hnRNP K expression (Figures 14, 15). Next, we asked whether this affected
the outcomes of the mice. Strikingly, mice that received hnRNP K-overexpressing FLCs had
substantially shortened overall survival compared to recipients of empty vector controls (Figure
16). Median survival for recipients of hnRNP K-overexpressing FLCs was 7.2 weeks, while
median survival for recipients of empty vector controls was not reached (p=0.02). Notably, mice
were flagged for euthanasia due to hyperpnea, emaciation, and failure to thrive.
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Figure 16. Survival of FLC recipients.

Kaplan-Meier curve of overall survival of mice

transplanted with FLCs containing an empty vector control (black; n=13) or hnRNP Koverexpression construct (green; n=20).

Bone marrow is abnormal in mice receiving hnRNP K overexpressing FLCs
We next sought to understand the basis of the shortened survival observed in mice that
received hnRNP K-overexpressing FLCs.

Since the transplanted FLCs were intended to

reconstitute the bone marrow of recipient mice, we first examined this compartment. Mice that
received FLCs overexpressing hnRNP K had more cellular bone marrow compared to empty
vector controls (Figure 17).

These cells were substantially skewed toward those with

morphologic features consistent with myeloid differentiation. In addition, mild eosinophilia was
observed.
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Figure 17. Recipients of hnRNP K-overexpressing FLCs have bone marrow abnormalities.
H&E staining of sternal bone marrow from representative mice transplanted with empty vector
control FLCs (left) or hnRNP K-overexpressing FLCs (right).

Recipients of hnRNP K overexpressing FLCs exhibit splenomegaly
To evaluate whether these bone marrow abnormalities affected other organs, we next
examined the spleen, since splenic abnormalities can reflect hematopoietic pathology.190 We
observed that recipients of empty vector control FLCs had spleens that were approximately the
size and weight of adult wildtype C57Bl6 animals191 (Figure 18)—consistent with efficient
engraftment of FLCs derived from C57Bl6 mice (Figure 14). However, mice that received hnRNP
K-overexpressing FLCs exhibited modest splenomegaly (Figure 18), which can be indicative of
hematopoietic disease.190
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Figure 18. Recipients of hnRNP K-overexpressing FLCs develop splenomegaly. A. Gross
images of spleens from representative mice transplanted with either empty vector FLCs (left) or
hnRNP K-overexpressing FLCs (right). B. Quantitation of spleen weights.

Recipients of hnRNP K-overexpressing FLCs have disrupted splenic architecture
We next sought to understand the basis of the splenomegaly in mice harboring hnRNP
K-overexpression. While recipients of control FLCs had splenic structure mimicking wildtype
C57Bl6 mice, those that received hnRNP K-overexpressing FLCs had markedly disrupted splenic
architecture (Figure 19). Critically, hnRNP K expression was still abundant in these spleens
(Figure 19A), supporting the notion that this aberrant hematopoiesis was driven by hnRNP Koverexpression. Spleens from hnRNP K-overexpressing mice had an increase in the number of
cells expressing the immature hematopoietic stem cell markers CD34 and CD117 (Figures 19B,
C). The presence of these cell types indicated that extramedullary hematopoiesis, a pathologic
process, was likely to be a factor underlying the observed splenomegaly.190
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Figure 19. hnRNP K overexpression results in splenic extramedullary hematopoiesis. A.
IHC staining of hnRNP K (A), CD34 (B), or CD117 (C) and corresponding H&E of spleen from
representative mice transplanted with empty vector FLCs (left) or hnRNP K overexpressing FLCs
(right). Additional images in panel B from the Hnrnpk OE mouse are included.
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Recipients of hnRNP K overexpressing FLCs have hepatic leukocyte infiltrates
Given the splenomegaly and altered splenic architecture in mice receiving hnRNP Koverexpressing FLCs, we next evaluated the liver, as this can be another site of extramedullary
hematopoiesis.190 We observed a striking infiltration of cells into the hepatic parenchyma of mice
receiving hnRNP K-overexpressing FLCs, but these cells were not present in mice transplanted
with control FLCs (Figure 20A). These cells stained largely negative for CD3, precluding the
notion that these might be a reactive infiltration of T cells (Figure 20B). A small subset of cells
stained positive for CD117 (Figure 20C), indicative of extramedullary hematopoiesis.
Interestingly, a large portion of these cells were CD14 positive, suggesting a monocytic lineage
(Figure 20D). Likewise, a subset of cells were also strongly positive for MPO (Figure 20E), often
utilized as a defining characteristic of myeloid lineage cells.192 Due to the absence of infiltrating
leukocytes, livers from recipients of control FLCs were completely negative for these markers.
Taken together, these findings demonstrate that hnRNP K-overexpression promotes hepatic
extramedullary hematopoiesis with a myeloid-lineage bias.
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overexpressing FLCs. A. H&E staining of liver from a representative mouse transplanted with
empty vector control FLCs (left) or hnRNP K-overexpressing FLCs (right).

B-E.

Higher

magnification immunohistochemistry in livers of representative mice transplanted with hnRNP Koverexpressing FLCs. Corresponding H&E staining is in the bottom panels.

Mice receiving hnRNP K-overexpressing FLCs have abnormal blood counts
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We next evaluated how this aberrant hematopoiesis affected the components of
peripheral blood. Recipients of hnRNP K-overexpressing FLCs showed an increase in total white
blood cell counts (Figure 21A). Likewise, a decrease in segmented cells (neutrophils) was
evident in these recipients compared with empty vector controls (Figure 21B). A slight increase
in lymphocytes was evident in hnRNP K-overexpressing FLC recipients (Figure 21C). Eosinophil
percentages were also significantly increased in the context of hnRNP K overexpression (Figure
21D).

Monocyte percentages were unchanged between groups (Figure 21E).

While not

statistically significant, the percentage of large immature cells (LICs), trended towards increased
in recipients of hnRNP K-overexpressing FLCs (Figure 21F). Differences in platelet count and
hemoglobin were not evident between groups (Figures 21G). These observations indicate that
hnRNP K-overexpression affects predominantly leukocytes, while largely sparing red blood cell
and platelet production.
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Figure 21. Peripheral blood counts in mice transplanted with FLCs. Bar graphs of A. White
blood cell count (WBC) B. Segmented cell percentage C. Lymphocyte percentage D. Eosinophil
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percentage E. Monocyte percentage F. Large immature cell (LIC) percentage G. Platelet (Plt)
count H. Hemoglobin (Hgb) in recipients of hnRNP K-overexpressing FLCs (red) or empty vector
control FLCs (black).

Peripheral blood smears are abnormal in recipients of hnRNP K-overexpressing FLCs
To visualize and confirm findings from our CBC analyses, we examined peripheral blood
smears from our mice.

Recipients of hnRNP K-overexpressing FLCs frequently had large

numbers of WBCs, with numerous leukocytes present in a high-powered field. We observed
myeloid cells in various levels of maturation (Figures 22B-E)—indicative of bone marrow stress.
In addition, several mice had large numbers of highly abnormal leukocytes appearing to be
myeloid in origin (Figures 22F-H). In line with the CBC data, circulating eosinophils were also
present (Figure 22I).
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Figure 22. Peripheral blood is abnormal in recipients of hnRNP K-overexpressing FLCs.
Wright-Giemsa staining of peripheral blood smears from an empty vector control (A) or recipients of
hnRNP K-overexpressing FLCs (B-I).

Red arrows indicate cells with morphologic features

consistent with bands (B), metamyelocytes (C), myelocytes (D), or promyelocytes (E). F-H highlight
other circulating abnormal leukocytes. I. Red arrows indicate eosinophils.
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3.4 Discussion
Based on our clinical observations of increased hnRNP K expression in AML and its
correlation with inferior clinical outcomes (Chapter 2), we proposed that hnRNP K may have
oncogenic capability when overexpressed. To formally test this hypothesis, we transplanted
mice with hematopoietic stem and progenitor cells (from the fetal liver) that were stably
transduced to overexpress hnRNP K. Recipients of these cells had substantially shortened
survival (Figure 16) and grossly aberrant hematopoiesis, characterized by bone marrow
harboring substantial morphologic myeloid hyperplasia, extramedullary hematopoiesis in the
spleen and liver, and circulating immature myeloid cells (Figures 17-22). These findings support
the notion that hnRNP K overexpression drives myeloproliferative disease in mice.
hnRNP K-overexpression in FLCs led to increased colony formation in methylcellulose
(Figure 12), suggesting that hnRNP K can alter a cell’s ability to self-renew and to differentiate.
Thus, our findings insinuate that hnRNP K overexpression may influence the stemness of
hematopoietic cells. It would then follow that compared to wildtype hematopoietic stem cells,
fewer hnRNP K-overexpressing cells would be required to reconstitute hematopoiesis in a
lethally-irradiated recipient mouse. While we did not perform these limiting dilution studies, these
future pursuits would be of interest.
Despite not being routinely reported in the literature, we used an empty vector control to
abrogate alterations in FLC characteristics due solely to transduction. Since the focus of this
chapter was on the influence of hnRNP K overexpression in a mouse model, however, we did
not fully characterize the impact of altered hnRNP K levels in the initial FLCs. Therefore, we
cannot definitively conclude that the hnRNP K-overexpressing FLCs transplanted into recipient
mice were immunophenotypically identical to the empty vector controls. However, we performed
our experiments with numerous primary transplant models and generated very similar results.
To characterize these models in greater depth, as well as to more quantitatively assess their
oncogenic properties, secondary transplants are currently underway. Preliminary data indicate
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cells from several primary recipients of hnRNP K-overexpressing FLCs have been successfully
transplanted into secondary recipients.
In these studies, we transplanted FLCs into immunocompromised NSG mice. While use
of these mice exponentially diminishes the probability of transplant rejection, due to a grossly
absent adaptive immune system, this is a suboptimal model for evaluating other aspects of
biology, particularly host immune response.193, 194 Since these cells are isolated from C57Bl6
mice, mice of this immunocompetent background are also suitable transplant recipients for these
FLCs.180 These mice are particularly useful models for evaluating treatment response, including
to immunotherapies.195,

196

Therefore, future studies transplanting hnRNP K-overexpressing

FLCs into immunocompetent mice would be worthwhile.
The myeloproliferative phenotype observed with hnRNP K overexpression in our FLC
transduction and transplantation model is particularly intriguing for several reasons. We have
recently described a mouse model wherein hnRNP K is overexpressed in the B-cell
compartment.83 These mice develop highly penetrant, transplantable B-cell lymphomas that
faithfully recapitulate clinical characteristics of human diffuse large B-cell lymphoma (DLBCL),
where we observed high expression of hnRNP K.83 Interestingly, none of the mice that received
hnRNP K-overexpressing FLCs in our current study developed lymphoma.

Since these

experiments placed hnRNP K-overexpression in hematopoietic stem cells, this suggests that
high hnRNP K expression favors myeloid differentiation. Consistent with this, microarray data in
normal human hematopoiesis revealed RNA expression of HNRNPK was substantially higher in
progenitor cells with a myeloid bias (common myeloid progenitors, granulocyte-monocyte
progenitors, or megakaryocyte-erythroid progenitors) than in lymphoid-committed progenitor
cells.171 Other groups have also confirmed this, with HNRNPK being observed at much higher
levels in myeloid-committed progenitors compared to lymphoid-biased cells.197
This notion that hnRNP K overexpression causes a myeloproliferative phenotype in our
current mouse model is also captivating given that a strikingly similar phenotype is observed in
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mice that are haploinsufficient for Hnrnpk.53 These mice also have shortened survival, mediated
most frequently by a phenotype involving myeloid hyperplasia, though a subset of Hnrnpk+/animals also develop lymphoma or other tumors.53 Such an observation strongly suggests that
normal hematopoiesis, particularly myelopoiesis, requires exquisitely tight regulation of hnRNP
K expression.
In particular, an interesting similarity between these two mouse models was eosinophilia
(Figures 21, 22). While myeloid malignancy can cause this phenomenon, more common causes
of eosinophilia include allergic reaction or parasitic infection.198 In our current study, we did not
observe any obvious infections in the mice. While the recipients of empty vector control FLCs
did not exhibit increased peripheral blood eosinophils, it is possible that hnRNP K-overexpressing
FLCs could confer an immunologic deficit to recipient mice, thus predisposing this group to
parasitic infections. However, the absence of visible signs of parasitic infection in these mice,
such as diarrhea, abdominal swelling, or substantial weight loss, diminish interest in this
possibility. In humans, rare cases of T-cell malignancies secreting cytokines (mostly IL-5) that
stimulate eosinophil production have also been described as a mechanism of eosinophilia.199
We did not evaluate IL-5 levels in our mice; however, it is possible that hnRNP K-overexpression
alters secretion of cytokines, including those that promote eosinophil development. Given that
increased eosinophils were evident in recipients of hnRNP K-overexpressing FLCs and Hnrnpk+/mice53, it is possible that this is a manifestation of the aberrant myeloid development driven by
hnRNP K. Of note, clinical eosinophilia is observed in cases of AML with core-binding factor
abnormalities, usually in cases of inv(16) or t(16;16), and occasionally t(8;21).200, 201 These
chromosomal aberrations result in altered RUNX1 transcriptional programs—a topic that will be
addressed in Chapters 4 and 5 as a possible mechanism of hnRNP K-mediated oncogenesis.
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Chapter 4
Examining the molecular basis of the oncogenic function of hnRNP K
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4.1 Introduction
In acute myeloid leukemia (AML), hnRNP K overexpression occurs in approximately 20%
of cases (Chapter 2).

This increased expression is correlated with decreased remission

durations and overall survival (Chapter 2). To formally test the hypothesis, then, that hnRNP K
is a yet uncharacterized oncogene in AML, we developed a mouse model wherein hnRNP K is
overexpressed in hematopoietic stem cells (Chapter 3). These mice developed hematologic
malignancies characterized by splenomegaly, abnormal blood counts, hepatic infiltration of
immature myeloid cells, and early death (Chapter 3). In this chapter, we aimed to define the
mechanisms by which overexpression of hnRNP K causes such disease by examining the
molecular basis of the oncogenic function of hnRNP K.
hnRNP K is a ssDNA/RNA-binding protein implicated in a myriad of biologic processes.
These include signal transduction39-43, chromatin remodeling44-47, transcription48-54, RNA
splicing55-59, mRNA stability60-62, and translation54, 63-69. In our recent model of B-cell lymphomas,
hnRNP K overexpression caused malignant transformation by stabilizing MYC RNA and
promoting translation of c-Myc.83 Contrastingly, HNRNPK haploinsufficient mice developed
myeloid neoplasms via transcriptional deregulation of Cdkn1a, Cebpa, and Cebpb.53
The multifunctionality of hnRNP K is due in large part to its composite domains. With
both a nuclear localization signal (NLS) and a nuclear shuttling domain (KNS), hnRNP K can
move bi-directionally between nucleus and cytoplasm.70,

71

This protein contains three K

homology (KH) domains, which recognize single-stranded nucleic acid—either DNA or RNA.74
In addition, an unstructured region (K-interactive [KI]) resides between the terminal KH domains,
and is where most known protein interactions occur.72, 73 This domain allows hnRNP K to be part
of multi-protein complexes, which may affect its nucleic acid binding activities. 41, 73
In this chapter, we sought to determine which of hnRNP K’s functions was most critical
to the development of myeloid neoplasia in the context of hnRNP K overexpression.
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4.2 Materials/Methods
Immunoprecipitation-mass spectrometry: OCIAML3 cells were transduced with pCDH-510-rtTAEF1-puro202 and pCDH-TRE-HNRNPK-EF1-CopGFP prior to selection in puromycin and
fluorescence-activated cell sorting for GFP-positive cells. Cells transduced with pCDH-TREEF1-CopGFP plasmid served as negative (empty vector) controls. hnRNP K overexpression
was induced by exposing cells to 1 µg/mL of doxycycline for 32 hours. Nuclear and cytoplasmic
fractions were separated by dounce homogenization as described.203 Immunoprecipitation was
performed with antibodies against hnRNP K (D6, Santa Cruz Biotechnology, Dallas, TX, USA)
or IgG (ab18413, Abcam, Cambridge, MA, USA). Proteins immunoprecipitated out of solution
were resolved on a 4-15% SDS-PAGE gel and silver stained (catalog# 24612, Thermo Fisher,
Waltham, MA, USA). Bands of visibly different intensities were excised and digested in the gel
with 200ng of sequencing grade trypsin (Promega, Madison, WI, USA) at 37°C for 18 hours. The
extracted bands were then analyzed by high-sensitivity liquid chromatography with tandem mass
spectrometry (LC-MS-MS) with an orbital ion-trap mass spectrometer (Orbitrap Elite, Thermo
Fisher Scientific, Waltham, MA, USA). Proteins were subsequently identified by searching the
fragment spectra against the SWISS-PROT database204 (EBI) using Mascot205 (Matrix Science,
Boston, MA, USA) or Sequest206 (Thermo Fisher Scientific, Waltham, MA, USA). Further details
are available elsewhere.83

Formaldehyde-RNA immunoprecipitation (fRIP): fRIP was performed using a modified protocol
described previously.207 100 million OCIAML3 cells were resuspended to a final concentration
of 1x106 cells/mL in RPMI 1640 media without FBS or antibiotics. Cross-linking was performed
via addition of formaldehyde to a final concentration of 0.25% and incubated at room
temperature. After 20 minutes, glycine at a final concentration of 125mM was used to quench
the reaction. Fixed cells were pelleted and resuspended in polysome lysis buffer (100mM KCl,
5mM MgCl2, 10mM HEPES (pH 7.0), 0.5% NP40, 1mM DTT, 100 units/mL RNaseOut (Thermo
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Fisher Scientific, Waltham, MA, USA), 400µM vanadyl ribonucleoside complex (VRC), and
protease inhibitor cocktail (Roche, Basel, Switzerland)) and left at -80°C overnight. After thawing
on ice, the suspension was lysed with a digital sonifier at 10% amplitude in 1 second bursts
followed by 4 seconds of rest for a total of 90 seconds. Lysates were subsequently cleared by
high-speed centrifugation at 4°C and pre-cleared using protein A and protein G beads in a 1:1
ratio. Beads coated with hnRNP K antibodies were suspended in NT2 buffer (50 mM Tris-HCl
(pH 7.4), 150mM NaCl, 1mM MgCl2, 0.05% IGEPAL) supplemented with RNaseOut, VRC, DTT,
and EDTA. Next, 10% of the pre-cleared lysate removed to serve as the “input” sample, and the
remainder was added to the bead slurry. The bead-lysate mixture was incubated while tumbling
at room temperature. After 2 hours, the mixture was washed four times with NT2 buffer.
Crosslinking was reversed in the lysates by addition of NaCl (final concentration 200 mM) and
proteinase K (final concentration 20mg/mL), incubated at 42°C for one hour, then moved to 65°C
for an additional hour. Remaining RNA was isolated using Trizol (Sigma-Aldrich, St. Louis, MO,
USA), purified, and concentrated with Zymo RNA Clean and Concentrator Kit, as per
manufacturer instructions (Zymo Research, Irvine, CA, USA).

Finally, RNA was reverse

transcribed to cDNA and subjected to single-read sequencing on an Illumina HiSeq 2000 at 36
nucleotides per read at the MD Anderson Sequencing Core. All samples were performed in
triplicate. These data is now publicly available under GSE126479 in the Gene Expression
Omnibus.83

fRIP analysis: Raw reads were trimmed to a minimum length of 25 base pairs using FLEXBAR.208
BOWTIE2209 was used to align trimmed reads to Genome Reference Consortium Human Build
38 (GRCh38),210 and outputted as .sam files, which were converted to .bam files using
SAMtools.211 This algorithm was then used to index, sort, and filter unique read counts per
alignment. Differential representation between input and immunoprecipitated (IP) samples was
done with Cufflinks, Cuffmerge, and Cuffdiff.212, 213 Using Cuffdiff, q-values were calculated
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comparing input to IP samples. Peaks were visualized in Integrative genomics viewer (IGV).214
Output was sorted by q-value, indexed, and subsetted by causal implication in cancers using
datasets of known tumor suppressors and oncogenes.215,

216

Further details with analysis

specifications are available elsewhere.83

Native RNA immunoprecipitation (RIP): OCIAML3 cells were lysed and processed according to
manufacturer’s instructions using the Magna-RIP RNA-binding protein immunoprecipitation kit
(Millipore, Burlington, MA, USA). In brief, cells were lysed in RIP lysis buffer and incubated with
magnetic beads and 5µg of either IgG or hnRNP K antibodies (3C2, Abcam, Cambridge, MA,
USA) at 4°C for three hours.

After washing, RNA-protein complexes were subsequently

disrupted by incubating with the presence of proteinase K. RNA was then extracted, purified,
and DNase treated at 37°C for one hour. Reverse transcription of RNA was performed as with
other PCR assays using iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). qRT-PCR was
performed with iTaq Universal SYBR green using an ABI StepOnePlus Real Time PCR machine.

Identifying putative hnRNP K binding sites: A computer-based algorithm was developed to scan
the RUNX1 transcript for possible hnRNP K binding sites. Putative hnRNP K consensus RNAbinding sequences67, 217 contained either ³2 (U/C)CCC motifs within 19 nucleotides or a motif
consisting of: CCAUCN2-7(A/U)CCC(A/U)N7-18UCA(C/U)C, where N is any nucleic acid. Further
details are available elsewhere.83

Recombinant hnRNP K protein expression and purification:

Using ligation-independent

cloning218, the DNA sequence encoding full-length hnRNP K was placed into the pNic28-Bsa4
plasmid with a TEV protease cleavage site immediately upstream of HNRNPK.

E. coli

transformed with this plasmid were grown at overnight at 37°C in auto-induction media. After
62

centrifugation, cell pellets were stored at -80°C overnight, thawed, and resuspended in 50mM
HEPES, 300mM NaCl, 10% glycerol, 0.5mM TCEP, complete protease inhibitors, 0.5mg/mL
lysozyme, and 20µg/mL DNase at pH 8.0 and lysed by sonication. Lysate was then centrifuged
at 18,000 rpm for one hour at 4°C. Full-length hnRNP K protein was purified from the clarified
lysate with Ni-NTA resin in 50mM HEPES with 300mM NaCl at pH 8.0. To remove contaminating
proteins, the resin was washed with 50mM HEPES, 300mM NaCl, and 20mM imidazole.
Recombinant hnRNP K protein was eluted with 500mM imidazole. His6-TEV protease was used
to cleaved the N-terminal His-tag during dialysis against 50mM HEPES, 150mM NaCl, and
0.5mM TCEP at pH 7.5. This solution was passed through the Ni-NTA column to remove the
cleaved His-tag as well as the remaining TEV protease. Size exclusion chromatography was
then performed using a Superdex 200 column equilibrated with 20mM HEPES, 200mM NaCl,
5% glycerol, and 0.5mM TCEP at pH 7.5. After these steps, SDS-PAGE analysis indicated the
recombinant full-length hnRNP K protein was >95% pure.

Fluorescence anisotropy: RNA oligonucleotides with a 5’ 6-FAM label were purchased from
Sigma Aldrich (St. Louis, MO, USA) and used at a final concentration of 2nM. Sequences are
included in Table 3. Recombinant hnRNP K protein, serially diluted in PBS to range from 0.1nM
to 10µM, was added to the oligos. Fluorescence anisotropy (FA) values were measured with
excitation wavelength 485nm and emission wavelength detected at 528nm on a Synergy Neo
multi-mode plate reader (BioTek, Winooski, VT, USA). Fluorescein at 10nM was used as an
internal standard. All readings were done at room temperature and performed in at least
triplicate.

FA data was analyzed with Prism 8.

Data was fit to the following equation:

FA=FAi+Bmax*[oligo]/(Kd+[oligo]) where initial FA is represented by FAi and the overall change in
FA is represented by Bmax. Here it is relevant to note that I adore penguins as much as Sean
Post loves Bmax.
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Human
Name
hRUNX1 1bs
hRUNX1 2bs
hRUNX1 3bs
hRUNX1 5' UTR
hRUNX1 5' UTR (mut)
hRUNX1 int5-6
hRUNX1 int5-6 (mut)

Sequence
UCCCCUC
UCCCCUCCCC
UCCCCUCCCCUCCC
CGCCCCCCCCCACCCCCCGCAGUAAUAAAGGCCCCUGA
CGCGCGCGCGCACGCGCCGCAGUAAUAAAGGCGCCUGA
UCUCUUCCCUCCCUCCUUCCCUCCCCCCAU
UCUGUUCGCUCGCUCGUUCGCUCGCGCCAU
Mouse

Name
mRunx1 intron 5-6
mRunx1 intron 5-6 (mut)

Sequence
UCCUCCUCCCUUCCCCUCCCGGUCCCUA
UCCUCCUCGCUUCGCCUCGCGGUCGCUA

Table 3. Fluorescence anisotropy oligos. Human and mouse sequences of RNA oligos used
for fluorescence anisotropy assays. Sequences are listed from 5’ to 3’. Red letters highlight
where mutations were made.

Thermal shift assay: The thermal shift assay was performed in a 96-well plate using SYPRO
orange dye in a StepOne Plus Real Time PCR System (Applied Biosystems, Foster City, CA,
USA). The reaction was prepared in PBS buffer and contained 5µM of recombinant hnRNP K
protein, SYPRO orange dye at a final concentration of 2X and DNA oligos at 1µM, 2.5µM, and
5µM. Oligos used were the DNA equivalents to those used in the fluorescence anisotropy
assays. The total reaction volume was 20µL and 4 technical replicates were done for each
sample. Negative control samples containing no protein were also run on the same plate. The
samples were heated from 25°C to 99°C and the fluorescence measured at each temperature
increment. The first derivative of fluorescence was calculated at each temperature and the
temperature corresponding to the minima was designated as the melting temperature of the
sample.
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4.3 Results
hnRNP K interacts with RNA processing machinery and ribosomal subunits
Given the plethora of cellular processes in which hnRNP K has been implicated, we
performed hnRNP K immunoprecipitation (IP) followed by mass spectrometry to identify proteins
with which hnRNP K interacts. In a human AML cell line, OCIAML3, compared to IgG IP, hnRNP
K IP pulled down multiple proteins that were clearly visible after silver staining (Figure 23A). This
was true in both cytoplasmic and nuclear fractions of OCIAML3 cells. Endogenous cytoplasmic
hnRNP K was found to interact with numerous ribosomal proteins (Figure 23B). In the nucleus,
hnRNP K interacting partners were enriched for RNA-binding proteins in addition to ribosomal
proteins (Figure 23B). Gene ontology (GO) analyses219 from each fraction indicate hnRNP K
interacts with proteins involved in translation and RNA binding/modification (Figures 23C,D).
Together, this strongly indicates that hnRNP K is involved in post-transcriptional processes.

65

Gallardo et al Supplementary Figure 4

Cytoplasmic

B

K
hn

Ig
G

K

M

hn
K

M

Ig
G

Ig
G

M

hn
K

A

Ig

M

A

hn

A

G

Gallardo et al Supplementary Figure 4

Nuclear

Cytoplasmic

Nuclear

Cytoplasmic
RS9

RS3A

Nuclear

Cytoplasmic

RL12

RS18

RT29

RT18B

RT05

RL28

RS11

RL8

RS4X
RS18
RL18

RL17

RL24

RM12

RL32

RS9

RS3A

RLA0
RL24

RL12 RT09

RS4X

RL28

RS11

RL8

RS18
hnRNP K

RS2

RL18

RL24

HNRH3

ROA0

hnRNP K

RNA-binding proteins

MOV10

GOTERM BP

# -log(p-value)

SRP-dependent cotranslational protein targeting to membrane
viral transcription
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
translational initiation
rRNA processing
translation
ribosomal large subunit assembly
cytoplasmic translation
ribosome biogenesis

15
15
15
15
15
15
2
2
2

GOTERM MF

# -log(p-value)

structural constituent of ribosome
poly(A) RNA binding
rRNA binding
RNA binding
5.8S rRNA binding
protein binding
small ribosomal subunit rRNA binding

15
16
6
9
2
16
2

GOTERM CC

# -log(p-value)

ribosome
focal adhesion
cytosolic large ribosomal subunit
extracellular matrix
cytosolic small ribosomal subunit
cytosol
membrane
extracellular exosome
intracellular ribonucleoprotein complex
small ribosomal subunit
nucleolus
cytoplasmic ribonucleoprotein granule
nucleoplasm
nucleus
polysome
cytoplasm

13
12
8
10
7
16
14
14
6
4
8
3
8
11
2
10

Key:

p-value = 0.001

p-value = 0.001

78.95
78.95
78.95
78.95
78.95
78.95
10.53
10.53
10.53

3.24E-29
4.44E-28
1.09E-27
8.70E-27
hnRNP
5.66E-24
6.26E-23
2.23E-02
2.65E-02
3.79E-02

Histones

% PValue
78.95
84.21
31.58
47.37
10.53
84.21
10.53

8.92E-24
1.46E-15
4.83E-10
3.80E-08
3.20E-03
6.14E-03
8.50E-03

% PValue
68.42
63.16
42.11
52.63
36.84
84.21
73.68
73.68
31.58
21.05
42.11
15.79
42.11
57.89
10.53
52.63

3.84E-21
1.07E-14
2.26E-13
2.98E-12
4.38E-12
3.59E-09
5.32E-09
1.09E-07
1.70E-07
2.33E-06
1.00E-05
2.73E-04
1.30E-02
1.95E-02
3.69E-02
4.53E-02

XRN2

Other
RBMX

D Nuclear
Nuclear Fraction NUCL
CATG Fraction
GOTERM BP

K

CATG
TIMP3

ROA2

B

% PValue

RALY

HNRPC
HNRH3

MATR3

RNA-binding proteins

p-value < 0.001

GOTERM MF

# -log(p-value)

pol y(A) RNA bi ndi ng
structural consti tuent of ri bosome
nucl eoti de bi ndi ng
protei n bi ndi ng
nucl ei c aci d bi ndi ng
rRNA bi ndi ng
RNA bi ndi ng
mRNA bi ndi ng
protei n ki nase bi ndi ng
mRNA 3'-UTR bi ndi ng
core promoter bi ndi ng
si ngl e-stranded DNA bi ndi ng
pol y(A) bi ndi ng
N6-methyl adenosi ne-contai ni ng RNA bi ndi ng
pol y(G) bi ndi ng
tel omerase RNA bi ndi ng
AU-ri ch el ement bi ndi ng

39
18
15
38
15
5
24
5
4
3
3
3
2
2
2
2
2

p-value < 0.001

GOTERM CC

# -log(p-value)

i ntracel l ul ar ri bonucl eoprotei n compl ex
ri bosome
nucl eopl asm
cytosol i c smal l ri bosomal subuni t
catal yti c step 2 spl i ceosome
vi ral nucl eocapsi d
extracel l ul ar matri x
membrane
smal l ri bosomal subuni t
extracel l ul ar exosome
mi tochondri al smal l ri bosomal subuni t
nucl eus
spl i ceosomal compl ex
focal adhesi on
cytosol i c l arge ri bosomal subuni t
nucl eol us
cytopl asmi c ri bonucl eoprotei n granul e
mi tochondri al i nner membrane
nucl ear chromati n
CRD-medi ated mRNA stabi l i ty compl ex
l arge ri bosomal subuni t
cytosol
tel omerase hol oenzyme compl ex
nucl ear euchromati n
cytopl asm
pol ysome
mi tochondri on

17
12
29
8
9
7
11
22
6
22
5
30
6
9
5
11
4
8
5
2
2
14
2
2
18
2
7

HNRDL

CAPR1

DDX17
# -log(p-value)
SFPQ

transl ati on
15
SRP-dependent cotransl ati onal protei n targeti ng to membrane
11
vi ral transcri pti on
11
mRNA spl i ci ng, vi a spl i ceosome
13
nucl ear-transcri bed mRNA catabol i c process, nonsense-medi ated decay 11
transl ati onal i ni ti ati on
11
rRNA processi ng
12
gene expressi on
8
mi tochondri al transl ati onal el ongati on
7
7
mi tochondri al transl ati onal termi nati on
RNA processi ng
7
mRNA processi ng
7
negati ve regul ati on of mRNA spl i ci ng, vi a spl i ceosome
4
RNA spl i ci ng
6
osteobl ast di ﬀerenti ati on
5
negati ve regul ati on of tel omere mai ntenance vi a tel omerase
3
3'-UTR-medi ated mRNA stabi l i zati on
3
negati ve regul ati on of transl ati on
3
CRD-medi ated mRNA stabi l i zati on
2
ri bosomal l arge subuni t assembl y
2
DNA damage response, detecti on of DNA damage
2
ri bosome bi ogenesi s
2

Ribosomal proteins

HNRPQ
ELAV1

ROA0

SRSF7
%

HNRPU

PValue
ROA1

34.09
1.12E-15
ROA2
25 3.04E-14
25 1.84E-13
29.55 2.26E-13
25 3.42E-13
25 1.43E-12
27.27 4.48E-12
18.18 2.94E-11
15.91 7.38E-08
15.91 7.92E-08
15.91 1.63E-07
15.91 5.93E-06
9.091 2.01E-05
13.64 6.31E-05
11.36 1.42E-04
6.818 4.16E-04
6.818 8.50E-04
6.818 0.00967
4.545 0.01274
4.545 0.05245
4.545 0.08826
4.545 0.08826

Histones

%
9E-40
2E-21
9E-14
3E-06
8E-08
3E-06
2E-23
3E-04
0.07
0.007
0.012
0.023
0.033
0.018
0.018
0.04
0.042

%
38.64
27.27
65.91
18.18
20.45
15.91
25
50
13.64
50
11.36
68.18
13.64
20.45
11.36
25
9.091
18.18
11.36
4.545
4.545
31.82
4.545
4.545
40.91
4.545
15.91

PValue
1.12E-15
3.04E-14
1.84E-13
2.26E-13
3.42E-13
1.43E-12
4.48E-12
2.94E-11
7.38E-08
7.92E-08
1.63E-07
5.93E-06
2.01E-05
6.31E-05
1.42E-04
4.16E-04
8.50E-04

PValue
8.25E-24
1.15E-13
1.80E-13
1.67E-11
3.88E-11
4.35E-11
1.31E-09
3.52E-09
4.47E-09
2.76E-07
3.3E-07
3.50E-07
2.7E-06
3.14E-06
2E-05
2.34E-05
2.7E-05
7.03E-05
0.00109
0.01408
0.03254
3.79E-02
0.04842
0.06183
8.19E-02
0.08594
9.06E-02

Figure 23. Immunoprecipitation followed by mass spectrometry reveals hnRNP K

interacting partners. A. Silver stain of SDS-PAGE blots from OCIAML3 cells fractionated to
p-value = 0.001
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hnRNP K (hnK). Red arrows indicate bands that were excised and sent for mass-spectrometry.
B. Proteins co-immunoprecipitated with hnRNP K were visualized with Cytoscape.220 C-D. Gene
p-value < 0.001

ontology (GO) analyses of proteins immunoprecipitated with hnRNP K in cytoplasmic (C) or
nuclear (D) fractions. Blue bars divide proteins by biologic process and green bars divide
proteins by molecular function. Bars indicate statistical significance of proteins falling into the
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Othe

associated categories. Figure partially reproduced with permission from Gallardo & Malaney et
al., JNCI, 2019.83

hnRNP K interacts with numerous RNA transcripts, including RUNX1
As indicated by the hnRNP K IP-MS, hnRNP K interacts with numerous proteins that bind
RNA and/or are involved in RNA processing. To understand how modulation of RNA species
might contribute to leukemogenesis, we sought to identify the RNA targets with which hnRNP K
interacts.

Formaldehyde-RNA immunoprecipitation followed by sequencing revealed that

hnRNP K was associated with numerous transcripts, including many involved in cancer
progression. When evaluated in the context of known tumor suppressors or oncogenes, one of
the most significant hnRNP K-associated transcripts was that of RUNX1, which a critical
transcription factor for both normal and malignant hematopoiesis221 (Figure 24).

RUNX1

Figure 24. hnRNP K binds to the RUNX1 transcript. Depiction of hnRNP K-associated
transcripts as determined by fRIP analyses. Results are subsetted based on a list of known
oncogenes/tumor suppressors. The dotted line indicates a cutoff representing a q-value of 0.05.
Figure modified with permission from Gallardo & Malaney et al., JNCI, 2019.83
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hnRNP K interacts with RUNX1 transcript

Native RIP OCIAML3

To validate the finding from fRIP-Seq that hnRNP K interacts with RUNX1, we performed
native RIP followed by PCR. Indeed, RUNX1 mRNA was substantially enriched after hnRNP K
IP compared to input (Figure 25). This supports the notion that hnRNP K interacts with RUNX1
in human AML cells.

RUNX1
Fold change vs IgG

600

Input
hnRNP K

450
300
150
0

Input

hnRNP K IP

Figure 25. RUNX1 mRNA interacts with hnRNP K. Bar graph illustrating fold change of
RUNX1 RNA in input sample of OCIAML3 cells compared with hnRNP K IP. Data is represented
as fold change of input (black) or hnRNP K IP (red) as compared to IgG IP.

RUNX1 RNA harbors putative hnRNP K binding sites
Given our fRIP and RIP data indicating that hnRNP K binds human RUNX1, we sought
to determine whether this occurred in a sequence-specific manner. Knowing that hnRNP K is a
poly-C binding protein222, we used a computer program to scan the human RUNX1 transcript for
multiple stretches of at least three cytosine residues. We identified two putative hnRNP K binding
sites in the human RUNX1 transcript (Figure 26).

One binding site was located in the 5’

untranslated region (UTR) of the majority of RUNX1 isoforms. No analogous hnRNP K binding
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site was identified in murine Runx1. In contrast, a second consensus hnRNP K binding site was
identified at an intron-exon boundary in human RUNX1; this site was also found in murine Runx1
isoforms (Figure 26). In the majority of RUNX1 isoforms, this site exists at the boundary of intron
3 and exon 4. Of note, we have referred to this site as intron 5-6, since this is its location in the
longest isoform of RUNX1 (RUNX1C; ENST00000300305.7).

Figure 26. Predicted hnRNP K binding sites in RUNX1. Poly(C) regions in the RUNX1
transcript are denoted by black boxes. A cluster of 2 poly(C) regions within 19 nucleotides or 4
poly(C) regions within 38 nucleotides constitutes the hnRNP K consensus binding sequence, as
reported in the literature67, 217; these are indicated in red.

hnRNP K binds tightly to poly(C) containing RNA
To evaluate whether hnRNP K was capable of directly binding the predicted sites in
RUNX1, we performed fluorescence anisotropy (FA) studies using recombinant hnRNP K
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protein. In these assays, a 6-FAM labelled RUNX1 RNA containing the predicted hnRNP K
binding site was placed into solution with recombinant full-length hnRNP K protein. In the
absence of protein binding, the fluorescently labelled oligonucleotide rotates rapidly in solution,
being measured as low anisotropy. Upon protein binding, the rotation of the oligonucleotide in
solution is reduced, and is measured as high anisotropy.223, 224 Oligos, derived from the RUNX1
transcript, containing 1, 2 or 3 poly(C) stretches were used in the FA assays. Multiple stretches
of poly(C) residues enhanced hnRNP K/RNA binding, (Figure 27), indicating more efficient
binding with oligos containing multiple stretches of poly(C) residues.

Figure 27. hnRNP K binds stretches of poly(C) RNA derived from RUNX1. A. Fluorescence
anisotropy curves as a function of increasing hnRNP K concentration. RNA oligos contained
increasing numbers of poly(C) regions derived from the RUNX1 intron 5-6 sequence. B.
Summary Kd values for data presented in panel A.

hnRNP K specifically binds RUNX1 RNA
It is clear that hnRNP K stringently binds portions of RNA derived from the RUNX1
transcript. To evaluate whether hnRNP K was capable of binding larger portions of RUNX1 that
may form secondary structures, we performed fluorescence anisotropy studies with longer
portions of the endogenous RUNX1 RNA. At all predicted hnRNP K binding sites—5’ UTR in
human and intron 5-6 in human and mouse—hnRNP K was found to bind strongly (Figure 28).
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Critically, in each instance, mutations in that disrupted any triple C sequence markedly abrogated
hnRNP K binding (Figure 28). This demonstrates that hnRNP K is capable of binding RUNX1
RNA in a stringent, sequence-specific manner.

Figure 28. hnRNP K binds human and mouse RUNX1. Curves representing fluorescence
anisotropy as a function of increasing hnRNP K protein concentration. Oligos spanning the
predicted hnRNP K binding sequence in: A. the 5’ UTR of human RUNX1 or B. intron 5-6 of
human RUNX1. C. Summary Kd values of data from panels A and B. D. Oligos spanning the
predicted hnRNP K binding sequence spanning intron 5-6 of mouse Runx1.

Oligos derived from RUNX1 bind to and thermostabilize hnRNP K
As an orthogonal method to evaluate binding of hnRNP K to RUNX1 oligos, we performed
thermal shift assays. In these experiments, recombinant full-length hnRNP K is incubated with
SYPRO orange—a dye that becomes fluorescent upon binding hydrophobic amino acid residues.
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As the reaction is heated and protein begins to unfold, these hydrophobic residues are exposed,
and SYPRO orange binds. By measuring SYPRO orange fluorescence over a gradient of
temperatures, the melting temperature of a protein can be calculated. An increase in the melting
temperature of a protein, upon addition of any entity, such as a drug or a DNA oligo, indicates an
interaction between the protein and that entity.225
When recombinant full-length hnRNP K was incubated with oligos derived from RUNX1—
either at the 5’ UTR or at intron 5-6, a significant increase in the melting temperature of hnRNP
K was observed (Figure 29). Critically, these increases were abrogated in the presence of
mutated oligos, further suggesting that hnRNP K binds RUNX1 RNA in a sequence-specific
manner.

Figure 29. RUNX1 oligos thermostabilize hnRNP K. Bar graph representing the melting
temperature of hnRNP K upon interaction with increasing amounts of the indicated oligos derived
from human RUNX1. For each oligo, concentrations were 2.5µM and 5µM.
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4.4 Discussion
In Chapters 2 and 3, we determined that hnRNP K is overexpressed in AML, and is a
bona fide oncogene when overexpressed in a mouse model. In this chapter, we aimed to begin
identifying a mechanism by which hnRNP K exerts its oncogenic activity—a formidable
undertaking considering most descriptions of hnRNP K begin with a litany of its described biologic
functions.226 We therefore conducted hnRNP K IP-MS to provide direction as to which of these
biologic functions were most worthy of pursuit. In line with published literature, hnRNP K
interacted with a long list of proteins.227 However, the hnRNP K-interacting proteins we identified
in the context of AML were predominantly RNA-binding proteins and ribosomal subunits—entities
involved in post-transcriptional cellular processes.
We began our evaluation of hnRNP K as an RNA-binding protein with fRIP-Seq. In this
study, we identified RUNX1 as one of the top hnRNP K-interacting transcripts. This finding was
particularly intriguing as RUNX1 is a critical transcription factor in both normal and malignant
hematopoiesis. Definitive hematopoiesis does not occur in Runx1 knockout mice, resulting in
embryonic lethality, and heterozygous loss of Runx1 also results in aberrant hematopoiesis.85 In
leukemias of various lineages, RUNX1 is frequently translocated104-106, mutated109,

116, 228

, or

aberrantly expressed.98, 229-231 Therefore, an interaction between hnRNP K and an entity so
integrally involved in leukemogenesis was of great interest. Of note, RUNX1 was not identified
as an hnRNP K-interacting protein in our IP-MS data. Rather, the interaction was found between
hnRNP K protein and RUNX1 RNA.
We identified two hnRNP K binding sites in RUNX1 (Figure 26). To our knowledge, the
5’ UTR site has not been described, though others recently reported hnRNP K binding at the 3’
UTR in vitro.232 An hnRNP K-Runx1 interaction has been described at the intron 5-6 junction
during neuronal differentiation in rats.56 Indeed, this intron 5-6 sequence is largely conserved
between species149, which is also supported by our studies that hnRNP K stringently binds the
intron 5-6 junction in both human and mouse (Figures 28, 29). Disruptions in poly(C) stretches
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in the RUNX1 transcript dramatically reduce hnRNP K binding (Figures 28, 29). Together, this
is compelling evidence that hnRNP K interacts with RUNX1 RNA in a sequence-specific manner.
hnRNP K is overexpressed in AML (Chapter 2), a disease which often has aberrancies
in RUNX1.221 In this chapter, we presented compelling evidence that hnRNP K stringently and
specifically interacts with RUNX1 RNA. Hence, one mechanism of hnRNP K’s oncogenicity may
stem from its ability to interact with RUNX1. This hypothesis will be addressed in detail in Chapter
5.
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Chapter 5
Evaluating the functional consequence of the hnRNP K-RUNX1 interaction
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5.1 Introduction
hnRNP K is a versatile protein with roles in copious biologic processes including
chromatin remodeling44-47, signal transduction39-43, transcription48-54, RNA splicing55-59, mRNA
stability60-62, and translation54,

63-69

.

These functions are mediated in large part through its

capacity to bind single-stranded nucleic acid, either DNA or RNA, via its KH domains.74, 226 In
Chapter 4, we observed that hnRNP K stringently and specifically bound human and mouse
RUNX1 RNA near an intron-exon boundary.

Therefore, in this chapter, we examined the

possibility that hnRNP K has a role in regulating RUNX1 alternative splicing.
Splicing is a requisite step for the maturation of almost all human mRNAs, where noncoding introns are removed before translation occurs.121, 122 Further, a single pre-mRNA can give
rise to numerous distinctive mature mRNAs via differential utilization of splice sites—thus
including or excluding various exons—a process referred to as alternative splicing.125 Such a
process therefore allows a single gene to encode for multiple protein products.

Indeed,

alternative splicing is the major process underlying the disparity between the vast proteomic
diversity in cells and a much more limited array of protein-coding genes.117-120
Splicing occurs via processes involving macromolecular complexes referred to as the
major and minor spliceosome.125-127 Small nuclear ribonucleoprotein complexes (snRNPs) U1,
U2, U4, U5, and U6 comprise the major spliceosome.125 The minor spliceosome consists of U5,
U11, U12, U4atac, and U6atac, which are functionally analogous to the components of the major
spliceosome.126, 128 Sequence motifs at the 5’ splice site (5’ss; flanking the upstream exon and
intron) and the 3’ splice site (3’ss; flanking the intron and downstream exon) are required for
intron excision to occur.125 The 5’ss is recognized and bound by the U1 snRNP, while the U2
snRNP recognizes and binds the 3’ss.125, 126 U2 auxiliary factors (U2AFs) also bind the 3’ss and
facilitate binding of the U2 snRNP. Next, the U4/U5/U6 tri-snRNP is recruited, and the fully
assembled spliceosome splices the pre-mRNA via two sequential transesterification reactions.125
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Splice sites can be considered constitutive or alternative, depending on whether they are
always or only sometimes used, respectively.125,

142

In either case, the same spliceosomal

machinery catalyzes the splicing reaction. However, trans-acting splicing factors often mediate
recruitment efficiency of the spliceosome to alternative splice sites.142 Such trans-acting factors
are most often RNA-binding proteins that recognize sequence motifs that enhance/promote or
silence/repress splicing.233, 234 The canonical splicing enhancers are the serine/arginine-rich
proteins (SR proteins, such as SRSF2).142

In contrast, canonical splicing repressors are

heterogeneous nuclear ribonucleoproteins (hnRNPs, such as hnRNP K).142, 235 However, context
largely dictates whether a protein, even one from one of these canonical classes, will act as a
repressor or enhancer of splicing.142
Depending on where in a pre-mRNA a protein binds, as well as the capability of that
protein to interact with other proteins, one protein may have differential splicing effects around a
particular site.142 For example, hnRNP K binding to RUNX1 RNA near the 3’ss of intron 5-6 could
lead to competition with normal binding of U2AFs and/or the U2 snRNP. Indeed, in a rat cell line,
hnRNP K competed with U2AF2 (also known as U2AF65) for binding to the poly(C) tract
immediately upstream of 3’ splice sites of several genes.56 Depending, then, on the interaction
between hnRNP K and the U2 snRNP, hnRNP K may act as a splicing repressor.
The role of splicing in hematologic malignancies has become increasingly recognized.
Mutations in splicing factors such as SF3B1, SRSF2, U2AF1, and ZRSR2 have been identified
in numerous leukemias, including AML.32, 34, 236, 237 Intriguingly, altered splicing events can occur
in AML even in the absence of mutations in splicing machinery.146 In one study of several tumor
types, AML samples had the highest rate of alternative splicing events, even when only analyzing
samples without splicing factor mutations.146

Furthermore, dysregulation of the alternative

splicing process can give rise to protein isoforms with functions resulting in oncogenic insults—
even without concomitant genomic aberrations.147,

148

Thus, our understanding of these

processes is imperative to reveal the underpinnings of leukemogenesis.
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RUNX1 is a key transcription factor in normal and malignant hematopoiesis.85

In

leukemias, RUNX1 is often mutated109, 116, 228, translocated104-106, or aberrantly expressed.98, 229231

Like the majority of protein-coding genes with more than one exon, RUNX1 is spliced. Indeed,

alternative splicing of RUNX1 results in an isoform lacking the C-terminus transactivation domain,
known as RUNX1A. Another alternatively spliced, less understood isoform of RUNX1, lacking
an internal 64 amino acid residues (corresponding to exon 6), has been identified in mouse and
human.88, 93, 149, 155 However, the mechanisms underlying the production and functional relevance
of these isoforms have not been fully elucidated.
hnRNP K has been shown to influence splicing of several genes, including RUNX1.56, 58,
59, 149-151

However, it is unclear what influence, if any, hnRNP K overexpression has on splicing

of RUNX1, particularly in the context of AML. Additionally, the physiologic relevance of the
hnRNP K-RUNX1 interaction has not been elucidated. In this chapter, we therefore aimed to
functionally characterize the interaction between hnRNP K and RUNX1.
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5.2 Materials/Methods
Viral production: HEK293T cells at 50% confluency in T75 flasks were transfected with 4 µg of
transfer vector (see plasmids section) and 4 µg of packaging vector. For virus used to infect
FLCs, the packing vector used was pCL-Eco (Addgene plasmid #12371).183 For virus used to
infect human cell lines, packaging was done with 4 µg of pCMV-dR8.2 (Addgene plasmid
#8455)238, and 800 ng of pCMV-VSV-G (Addgene plasmid #8454)238. This DNA was combined
with 12 µL of JetPrime DNA transfection reagent (Polyplus Transfection, New York, NY, USA).
Fresh medium was supplied after 6-8 hours (stem cell medium without cytokines for FLCs;
DMEM with 10% tetracycline-free FBS for human cell lines), and cells were incubated at 32°C
for 48-72 hours. High-titer viral supernatant was collected and passed through a 0.45 µm filter.

Fetal liver cell (FLC) isolation: The University of Texas MD Anderson Cancer Center Animal Care
and Use Committee approved all mouse experiments performed in these studies under protocols
0000787-RN01 and 0000787-RN02. Pregnant wildtype CD45.2+ C57/Bl6 females were
euthanized by exposure to CO2 at day 13.5 of gestation. Fetal livers were sterilely dissected and
gently disrupted on a 70 µm filter to obtain a single-cell suspension. The collected cells were
briefly subjected to a red blood cell (RBC) lysis with BD Pharm Lyse buffer (BD Biosciences, San
Jose, CA, USA). After RBC lysis, cells were resuspended in stem cell medium at ~3x106 cells/mL
and incubated at 37°C overnight prior to retroviral transduction. Stem cell medium contained 37%
DMEM (Corning Inc, Corning, NY, USA), 37% Iscove’s modified Dulbecco’s Medium (Corning
Inc, Corning, NY, USA), 20% fetal bovine serum, 2% L-glutamine (200mM; Corning Inc, Corning,
NY, USA), 100 U/mL penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA), 5x10-5 M 2mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), recombinant murine interleukin-3 (0.2
ng/mL), interleukin-6 (2 ng/mL), and stem cell factor (20 ng/mL; all cytokines were obtained from
Stem Cell Technologies, Vancouver, Canada).
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FLC transduction and sorting: Approximately 5x106 FLCs were resuspended in 2 mL of high-titer
retroviral supernatant supplemented with 12 µg/mL polybrene and fresh cytokines (IL-3, IL-6,
and SCF). Plates were then spun at 600xg for 90 minutes at room temperature and incubated
at 32°C for 48-72 hours. After transduction, cells with GFP were sorted for GFP positivity using
the MoFlo Astrios cell sorter (Beckman Coulter, Brea, CA, USA) at the MD Anderson Cancer
Center North Campus Flow Cytometry Core Facility.

RNA-Sequencing: RNA was extracted and purified from cells using Zymo Quick-RNA columns
as per manufacturer’s instructions (Zymo Research, Irvine, CA, USA).

Barcoded, Illumina

stranded total RNA libraries were prepared using the TruSeq Stranded Total RNA Sample
Preparation Kit (Illumina, San Diego, CA, USA). Briefly 250ng of DNase I treated total RNA was
depleted of cytoplasmic and mitochondrial ribosomal RNA (rRNA) using Ribo-Zero Gold
(Illumina, San Diego, CA, USA). After purification, the RNA was fragmented using divalent
cations and double stranded cDNA was synthesized using random primers. The ends of the
resulting double stranded cDNA fragments were repaired, 5′-phosphorylated, 3’-A tailed and
Illumina-specific indexed adapters are were ligated. The products were purified and enriched by
12 cycles of PCR to create the final cDNA library. The libraries were quantified by qPCR and
assessed for size distribution using the 4200 TapeStation High Sensitivity D1000 ScreenTape
(Agilent Technologies, Santa Clara, CA, USA) then multiplexed, 3 libraries per lane and
sequenced on the Illumina HiSeq4000 sequencer (Illumina, San Diego, CA, USA) using the 75
bp paired end format.

RNA-Seq analysis: Fastq files were pseudoaligned using Kallisto v0.44.0239 with 30
bootstrap samples to a transcriptome index based on the Mus musculus GRCm38
release (Ensembl). The resulting abundance data was further analyzed with Sleuth
v0.30.0240 using models with covariates for both batch and condition.

Gene-level
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abundance estimates were calculated as the sum of transcripts per million (TPM)
estimates of all transcripts mapped to a given gene. Wald tests were performed at a
gene level for the “condition” covariate with a significance threshold of FDR < 10%.

qRT-PCR: RNA was extracted and purified from cell lines using Zymo Quick-RNA columns as
per manufacturer’s instructions (Zymo Research, Irvine, CA, USA). Samples were subjected to
in-column DNAse treatment as per manufacturer’s instructions. Purified RNA was quantified
using a NanoDrop spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). 1µg of
RNA was reverse transcribed using iScript (BioRad, Hercules, CA, USA).

qRT-PCR was

performed using iTaq Univerval SYBR Green Supermix as per manufacturer instructions
(BioRad, Hercules, CA, USA) using an ABI StepOnePlus Real Time PCR System. Primers used
are listed in Table 4. Individual samples were assayed in triplicate. Calculations were performed
using the Pfaffl method comparing expression changes between target genes and housekeeping
control.158

Primer
Human PPIA Forward
Human PPIA Reverse
Human RPLP0 Forward
Human RPLP0 Reverse
Human RUNX1 Ex5 Reverse
Human RUNX1 Ghanem forward
Human RUNX1 Ghanem reverse
Human RUNX1 Ex3 forward (for total RUNX1)
Human RUNX1 Ex4 reverse (for total RUNX1)
Mouse Runx1 Ghanem Forward
Mouse Runx1 Ghanem Reverse
Mouse Runx1 Ghanem Total Forward
Mouse Runx1 Ghanem Total reverse

Sequence (5' to 3')
CCCACCGTGTTCTTCGACATT
GGACCCGTATGCTTTAGGATGA
CCTTCTCCTTTGGGCTGGTCATCCA
CAGACACTGGCAACATTGCGGACAC
CCATCAAAATCACAGTGGAT
GAAGTGGAAGAGGGAAAAGCTTCA
GCACGTCCAGGTGAAATGCG
CTGCTCCGTGCTGCCTAC
AGCCATCACAGTGACCAGAGT
CACTCTGACCATCACCGTCTT
GGATCCCAGGTACTGGTAGGA
TGGGATCCATCACCTCTTCCT
ACGGCAGAGTAGGGAACTGG

Table 4. Primers used in PCR. List of primers used in qRT-PCR and RT-PCR. All sequences
are listed from 5’ to 3’.
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RT-PCR for splicing analysis: One µg of RNA was converted to cDNA using iScript (BioRad,
Hercules, CA, USA) as per manufacturer’s instructions. PCR reactions were performed using
Apex buffer, 1.5mM MgCl2, 0.2mM of each dNTP, 0.5 units Taq polymerase, 0.5µM forward
primer, 0.5µM reverse primer, and 100ng cDNA. Primers used are included in Table 4. PCR
was run on a BioRad Thermocycler at 95°C x 3 minutes, followed by 35 cycles of 95°C for 1
minute, 60°C for 1 minute, and 72°C for 3 minutes, and finally 72°C for 5 minutes. After
amplification, equal amounts of PCR products were run on a 2% agarose gel with ethidium
bromide at 180V x 30 minutes, then visualized using a Syngene G:Box EF2 gel doc system with
GENESys image capture software.

Sanger sequencing: DNA was purified from agarose gels using a gel purification kit (Invitrogen,
Carlsbad, CA, USA) as per manufacturer’s instructions. 200ng of purified DNA and 1pmol of
each primer used in the PCR reaction were provided to the MDACC Sequencing and Microarray
Core Facility. Sequencing was performed on an ABI 3730XL sequencer using BigDye terminator
cycle sequencing chemistry with the forward primer used in the RT-PCR reaction. For validation,
another sequencing run was performed with the reverse primer used in the RT-PCR reaction.
Data analysis was provided as text files and chromatograms.

Plasmids and cloning:
hnRNP K mammalian cell expression plasmids: Full-length human hnRNP K cDNA was PCR
amplified using cDNA isolated from 293T cells as a template.

The PCR product was

subsequently digested with restriction enzymes XhoI and EcoRI and ligated into the
corresponding sites in the pcDNA c-flag vector (Addgene plasmid #20011).241 hnRNP K domain
deletions were amplified using the nested PCR technique242, and subsequently ligated into the
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XhoI/EcoRI restriction enzyme sites in the pcDNA c-flag vector. All of the above plasmids had
an in-frame C-terminal flag tag to verify expression and for downstream applications.

hnRNP K viral expression plasmids: Full-length hnRNP K and its domain deletions were amplified
using standard PCR techniques from the pcDNA c-flag plasmids, described above. These were
then cloned into the XhoI/NotI sites in the all-in-one tetracycline inducible lentiviral vector TRE3GORF-P2A-eGFP-PGK-Tet3G-bsd (TLO2026, transOMIC Technologies, Alabama, USA). All of
the viral plasmids had an in-frame C-terminal flag tag, and a P2A linker followed by eGFP. The
viral selection marker in the plasmid was blasticidin. These viral plasmids were used to generate
the tetracycline-inducible stable cell lines for overexpression of hnRNP K.
For fetal liver cell infection, retroviruses were made in an MSCV backbone and were
modified from those described previously.180
obtained from Addgene (plasmid #60832).180

MSCV-AML1/ETO-IRES-GFP plasmid was
The green fluorescent protein (GFP) coding

sequence was replaced with firefly luciferase ORF obtained from a luciferase-pcDNA plasmid
(Addgene plasmid #18964).182 For generation of empty vectors, AML1/ETO was excised using
EcoRI and BamH1 and plasmid re-ligated. To generate MSCV-HNRNPK-IRES-GFP and MSCVHNRNPK-IRES-Luciferase, AML1/ETO was replaced with HNRNPK that was PCR amplified
from HEK 293T cells.

RUNX1 mammalian expression plasmids: Full-length human RUNX1(b) cDNA was PCR
amplified using a RUNX1 expression plasmid as a template. The PCR product was subsequently
digested with restriction enzymes XhoI and EcoRI and ligated into the corresponding sites in the
pcDNA c-flag vector (Addgene plasmid #20011).241 RUNX1ΔEx6 was amplified using the nested
PCR technique and subsequently ligated into the XhoI/EcoRI restriction enzyme sites in the
pcDNA c-flag vector. Both plasmids had an in-frame C-terminal flag tag to verify expression and
for downstream applications.
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RUNX1 viral expression plasmids: Full-length RUNX1(b) and RUNX1ΔEx6 were amplified using
standard PCR techniques from the pcDNA c-flag plasmids, described above. These were then
cloned into the XhoI/NotI sites in the all-in-one tetracycline inducible lentiviral vector TRE3GORF-P2A-eGFP-PGK-Tet3G-bsd (TLO2026, transOMIC Technologies, Alabama, USA). All of
the viral plasmids had an in-frame C-terminal flag tag, a P2A linker followed by eGFP. The viral
selection marker in the plasmid was blasticidin. These viral plasmids were used to make
tetracycline-inducible stable cell lines for RUNX1 overexpression.
For infecting fetal liver cells, full-length RUNX1(b) and RUNX1ΔEx6 were subcloned from
the pcDNA c-flag plasmids into the MSCV-IRES-GFP vector (Addgene plasmid #20672).

RUNX1 luciferase reporter: An artificial oligo containing 13 consensus RUNX1 DNA binding sites
(TGTGG) flanked by HindIII restriction enzyme sites, and its corresponding reverse complement
pair, were synthesized. The two oligos were annealed and placed into HindIII sites in the PG13Luc vector (Addgene plasmid #16442).243 p53 binding sites from the PG13-Luc plasmid were
excised out during the HindIII digestion. The resulting RUNX1 reporter was referred to as RBGLuc.

All plasmids were verified by sequencing. The primers used for cloning are listed in Table 5.

84

Primer name
hnRNPK_FL_F
hnRNPK_FL_R
hnRNPK_dKH1_R
hnRNPK_dKH1_F
hnRNPK_dKH2_R
hnRNPK_dKH2_F
hnRNPK_dKI_R
hnRNPK_dKI_F
hnRNPK_dKH3_R
hnRNPK_dKH3_F
hnRNPK_dNLS_R
hnRNPK_dNLS_F
hnRNPK_dKNS_R
hnRNPK_dKNS_F
RBFLuc_F
RBFLuc_R
RUNXFL_F (pcDNA)
RUNXFL_R (pcDNA)
RUNXdelEx6_F
RUNXdelEx6_R
RUNXFL_F (transomic)
RUNXFL_R (transomic)
SIN3A_F
SIN3A_R

Sequence (5' to 3')
ATGCCTCGAGATAAAAGAATATGGAAACTGAACAGCCAGAAGAAAC
ATGCGAATTCTTACTTGTCATCGTCGTCCTTGTAGTCGAAAAACTTTCCAGAATACTGCTTCACACT
CTTCAGAATTTCTAATTCAACCATCTCATCAGTGTTTCTAGATCT
ATGGTTGAATTAGAAATTCTGAAGAAAATCATCCCTACCTTG
CCTATCGGGTTTCCTCAACTCGCAGTCAAAGTCACT
TGCGAGTTGAGGAAACCCGATAGGGTTGTAGAGTGC
AGCACTGAAACCAAAACCACCATAATCATAGGTTTCATCGTA
TATGGTGGTTTTGGTTTCAGTGCTGATGAAACTTGG
CTGGTCCTGTGTTGTAGTAATAATAGGTCCACCAAGATCACCATA
ATTATTACTACAACACAGGACCAGATACAGAATGCA
CTCATCAGTGTTACCAAATTCACCATTGGTTTCAGTG
GGTGAATTTGGTAACACTGATGAGATGGTTGAATTACGC
ACCCTGTGGTTCAACCATGCCGTCGTAACGGT
GACGGCATGGTTGAACCACAGGGTGGCTCC
AGCTTTGTGGTTTGTGGTTTGTGGTTTGTGGTTTGTGGTTTGTGGTTTGTGGTT TGTGGTTTGTGGTTTGTGGTTTGTGGTTTGTGGTTTGTGGTTA
AGCTTAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAAACCACAA
ATGCCTCGAGATGCGTATCCCCGTAGATGCCAGCAC
ATGCGAATTCTTACTTGTCATCGTCGTCCTTGTAGTCGTAGGGCCTCCACACGGCCTC
GAGAACCTCGAAATACAAGGCAGATCCAACCATCCCCACC
TCTGCCTTGTATTTCGAGGTTCTCGGGGCCCATCC
ATGCCTCGAGGCCGCCACCATGCGTATCCCCGTAGATGCCAGCAC
ATGCGCGGCCGCTCTTGTCATCGTCGTCCTTGTAGTCGTAGGGCCTCCACACGGCCTC
ATGCCTCGAGGCCGCCACCATGAAGCGGCGTTTGGATGACC
ATGCGGTACCTTACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAGGGGCTTTGAATACTGTGCCGTATTTG

Table 5. Primers used for cloning. List of primers used for cloning plasmids. All sequences
are listed from 5’ to 3’.

shRNAs: For knockdown of HNRNPK, SMARTvector inducible human HNRNPK PGK-TurboRFP
shRNAs were purchased from Dharmacon (Lafayette, CO, USA). Three plasmids were used
and referred to as shHNRNPK ex10 (clone ID: V3IHSPGR_10844995, mature antisense
TCGACGAGGGCTCATATCA, targeting exon 10), and two targeting the 3’ UTR, referred to as
shHNRNPK

ex16-1

(clone

ID:

V3IHSPGR_5114248,

mature

antisense

AAGACACTAGAGCAAATTG) and shHNRNPK ex16-2 (clone ID: V3IHSPGR_9103684, mature
antisense ATAAAATCCACTCACTCTG). A non-targeting PGK-TurboRFP (VSC11656, mature
antisense TGGTTTACATGTTGTGTGA; Dharmacon, Lafayette, CO, USA) control was utilized
within each experiment as an internal control. Puromycin was used as the viral selection marker.
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Transient transfections: 293T cells were plated at identical confluencies and transfected using
equal amounts of DNA with JetPrime reagents as per manufacturer’s instructions (Polyplus
Transfection, New York, USA). All transfections were for 48 hours unless otherwise noted.

Generation of stable cell lines: Virus was produced as described above. Approximately 0.5x106
cells were resuspended in 2 mL of high-titer viral supernatant supplemented with 12 µg/mL
polybrene. Plates were then spun at 600xg for 90 minutes at room temperature and incubated
at 32°C for 72 hours. After 72 hours, cells were spun down, viral supernatant removed, and cells
were resuspended in RPMI 1640 with 10% tetracycline-free FBS.

Appropriate selection

antibiotics were added to media (2-6µg/mL of blasticidin or 1-2 µg/mL of puromycin) and cells
were placed at 37°C. When cells began to grow through antibiotic selection (3-15 days), an
aliquot of cells was induced with doxycycline (0.2µg/mL for knockdown cell lines or 0.4µg/mL for
overexpression cell lines) for 24-72 hours before evaluation of appropriate fluorescent protein
expression by fluorescence microscopy was performed. If the appropriate fluorescent protein
expression (GFP and/or RFP) was observed in >90% of cells in response to doxycycline, cells
were utilized in downstream experiments.

All cells were maintained in constant antibiotic

selection and kept in stringently tetracycline-free conditions to avoid unintended gene induction.
Prior to cell harvest for each experiment, GFP and/or RFP expression were visualized by
fluorescence microscopy, and downstream assays only conducted if >90% of cells were
appropriately positive.

Western blotting: Cells were homogenized in NP40 lysis buffer containing protease and
phosphatase inhibitors (Millipore Sigma, Burlington, MA, USA). Soluble proteins were boiled in
Laemmli buffer, resolved on an SDS-PAGE gel, and transferred to a PVDF membrane.
Membranes were blocked with 5% milk for one hour at room temperature and incubated with
primary antibody at 4°C overnight while rocking. Primary antibodies were hnRNP K (3C2,
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1:1000, Abcam, Cambridge, MA, USA), RUNX1 (EPR3099, 1:1000, ab92336, Abcam,
Cambridge, MA, USA), b-actin (AC-15, 1:2000, Santa Cruz Biotechnology, Dallas, TX, USA).
Membranes were incubated with secondary antibody and antibody-protein interactions were
visualized using enhanced chemiluminescence (GE Healthcare, Chicago, IL, USA) or BCIP/NBT
color development substrate (VWR International, Radnor, PA, USA).

Luciferase assay: 293T cells were transiently transfected with luciferase-based reporter plasmids
and expression plasmids using jetPRIME (Polyplus, New York, NY, USA). Human V5-tagged
SIN3A pLX304 plasmid was purchased from Arizona State University Plasmid repository (clone
HsCD00445676; Tempe, AZ, USA). Total DNA quantity was constant across all wells. 48 hours
post-transfection, luciferase assay reagent was mixed in a 1:1 ratio with cell lysate in accordance
with manufacturer’s protocol (Luciferase Assay System kit, Promega, Madison, WI, USA;).
Luciferase activity was measured with Synergy H4 Hybrid Reader (BioTek, Winooski, VT, USA).
Transfection efficiency for each well was normalized using 62.5ng of a pCMV b-galactosidase
plasmid, which was co-expressed in each experiment. All experiments were performed in at
least triplicate.
Protein stability assays: 293T cells stably transduced with tetracycline-inducible constructs to
overexpress RUNX1, either full-length or lacking exon 6. 400ng/mL doxycycline was added to
cells prior to the addition of cycloheximide (10 µM, Sigma-Aldrich, St. Louis, MO, USA) with or
without MG-132 (10 µM, SelleckChem, Houston, TX, USA) were then added to cells for 1-8
hours. Cells were collected and lysed in NP40 lysis buffer with protease and phosphatase
inhibitors prior to western blot.

Colony formation assay: GFP sorted FLCs were cultured in quadruplicate wells of a 12-well plate
in methylcellulose medium with cytokines IL-3, IL-6, erythropoietin, and stem cell factor
(Methocult GF M3434, StemCell Technologies, Vancouver, Canada). 50,000 cells were plated
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per well and colonies were counted after 7 days. Colonies were gently disrupted in PBS and
cells counted manually with a hematocytometer using trypan blue dye exclusion, or subjected to
cytospin or flow cytometry. Cytospins were stained with Wright-Giemsa.

Polysome fractionation assay: This assay was performed using a previously described
protocol.244

293T cells were transfected with a non-targeting control (siScramble; 5’-

UAAGGCUAUGAAGAGAUAC-3’)
GAGCGCAUAUUGAGUAUCA,

or

a

pool

of

siHNRNPK

(5’-3’:

GAUCUUGGUGGACCUAUUA,

GGUCAGCGGAUUAAACAAA, GUCGGGAGCUUCGAUCAAA)
(Dharmacon, Lafayette, CO, USA) using JetPrime (Polyplus, New York, NY, USA) as per
manufacturer’s instructions. 24 hours after transfection, cells were split and harvested 72 hours
later. 10 minutes prior to harvest, 100mg/mL cycloheximide was added. Cells were collected
using trypsin, pelleted, and washed with cold PBS supplemented with cycloheximide. Lysis was
performed with polysome extraction buffer (20mM Tris-HCl pH 7.5, 100mM KCl, 5mM MgCl2,
and 0.5% Nonidet P-40) with added cycloheximide, protease inhibitors, and RNA inhibitors.
Lysate was centrifuged to clear insoluble material, then loaded onto a 0-50% sucrose gradient
and spun in an ultracentrifuge at 35000 rpm at 4°C for 3.75 hours. The gradient was then
fractionated into 28 fractions with a piston gradient fractionator (BioComp, Fredericton, NB,
Canada). Polysome profiles were created using absorbance readings at 260nm and aligned by
manually identifying peaks, and scaling positions with linear transformation. The minimum
absorbance value from each sample was subtracted out in order to account for background
absorbance. RNA from each fraction was isolated using Trizol, reverse transcribed, and utilized
for downstream qPCR analysis as described above. Further details are available elsewhere.83
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5.3 Results
hnRNP K globally affects splicing
Given the stringent binding of hnRNP K to RNA, and the increasing emphasis on aberrant
RNA splicing in myeloid malignancies, we sought to evaluate whether hnRNP K could influence
splicing patterns. To this end, we performed RNA-Seq on FLCs overexpressing hnRNP K
compared to empty vector controls. In addition to notable gene expression differences between
groups (Figure 30), hnRNP K influenced splicing of numerous transcripts (Figure 31).
Hnrnpk OE

Empty vector

Figure 30. Hnrnpk overexpression results in differential gene expression in murine FLCs.
Heatmap of the most differentially expressed genes in FLCs overexpressing hnRNP K (left)
compared to empty vector controls (right). Each column represents a biologic replicate.
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Runx1

p-value rank
Figure 31. Hnrnpk overexpression alters splicing in FLCs. Plot of differentially spliced
transcripts in Hnrnpk overexpressing FLCs compared with empty vector controls. Orange dots
represent transcripts that were differentially spliced in a statistically significant manner. Blue dot
indicates Runx1.

hnRNP K alters splicing of Runx1
One of the most compelling differentially spliced transcripts from our RNA-Seq data was
Runx1 (Figure 31). Since the Runx1 transcript has an hnRNP K binding site at the junction of
intron 5 and exon 6, near the 3’ splice site (Figures 26, 28, 29), we checked for Runx1 splice
variants with alterations in exon 6. Samples overexpressing hnRNP K had a statistically
significant increase in the amount of Runx1 exon 6 skipping compared to empty vector controls
(Figures 32A, B). We refer to this isoform as Runx1DEx6. While both isoforms of Runx1 were
present in all samples, Runx1DEx6 was more abundant in samples overexpressing Hnrnpk.
Therefore, we sought to more specifically evaluate the impact of hnRNP K in this area. To
validate these RNA-Seq findings, we performed Runx1 RT-PCR with primers spanning exons 590

7. In FLCs that were infected with Hnrnpk overexpressing virus, a PCR product corresponding
to the predicted size of Runx1DEx6 was dramatically enriched compared to controls (Figure
32C).

Figure 32. Runx1 is differentially spliced in hnRNP K overexpressing FLCs. A. Sashimi
plot of Runx1 exons 5-7 from a representative empty vector sample (top) and an Hnrnpk
overexpressing sample (bottom). Y-axis shows the number of reads. Numbers above lines
between exons represent the number of reads spanning those exon junctions. B. Data from four
empty vector samples and four Hnrnpk overexpressing samples represented as a fraction of total
Runx1 reads. C. Runx1 RT-PCR from FLCs infected with empty vector or Hnrnpk . As an
additional control, FLCs exposed to Hnrnpk OE virus but that were not infected (GFP neg) were
included. GFP+ indicates FLCs that successfully integrated the Hnrnpk construct and were
FACS sorted for GFP positivity. Empty vector controls were also sorted for GFP positivity.
Gapdh is shown as a loading control.
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Exclusion of RUNX1 exon 6 occurs in an hnRNP K-dependent manner
Given that exclusion of exon 6 (appearance of Runx1DEx6) occurred in FLCs in an
hnRNP K-dependent manner, and since the hnRNP K binding site in intron 5-6 is largely
conserved between mouse and human, we hypothesized that RUNX1 splicing surrounding exon
6 would be similarly affected in human cells. To this end, we generated several human AML cell
lines with doxycycline-inducible hnRNP K overexpression (Figure 33A). We then utilized PCR
primers to amplify RUNX1 with a forward primer in exon 5, and a reverse primer in exon 7 (Figure
33B).149 With this strategy, we were able to distinguish clear alterations in RUNX1 splicing
patterns surrounding this exon that were dependent on hnRNP K expression levels (Figure 33C).
This is consistent with the findings from our RNA sequencing of murine fetal liver cells, where
hnRNP K overexpression leads to an enrichment of Runx1DEx6 (Figure 32).
To confirm that the smaller band (160bp) visualized in RT-PCR was indeed the expected
product lacking exon 6, we performed Sanger sequencing on the PCR products. From these
results, it was evident that the larger band in these gels included exon 6, whereas the smaller
band completely lacked exon 6, leaving a clean junction between exons 5 and 7 (Figure 33D-H).
Therefore, cells overexpressing hnRNP K have an increase in RUNX1DEx6.
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Figure 33. hnRNP K overexpression leads to exclusion of RUNX1 exon 6. A. Western blot
of stable human AML cell lines with tetracycline-inducible empty vector control (ctrl) or hnRNP K
overexpression (hnK OE). Cells were treated with doxycycline for 24 hours prior to harvest. B.
PCR strategy for RUNX1 amplification. C. RT-PCR from the indicated human AML cell lines
treated with doxycycline for 24 hours to overexpress an empty vector (Ctrl) or hnRNP K (hnK
OE). PPIA serves as a loading control. D. RUNX1 RT-PCR from 293T cells. Ladder with
associated number of base pairs (bp) is clearly labeled. E. Sanger sequencing of 352 bp band
from gel in panel A. Double lines are placed in lieu of the entirety of exon 6 sequencing results.
F. Schematic of the exons present in the PCR product containing exons 5-7, herein referred to
93

as RUNX1 FL (full length). Arrows indicate the location of RT-PCR primers. G. Sanger
sequencing of 160 bp band from gel in panel A. H. Schematic of the exons present in the PCR
product lacking exon 6. Arrows indicate the location of RT-PCR primers.

hnRNP K knockdown favors inclusion of RUNX1 exon 6
In both human and mouse, hnRNP K overexpression led to an accumulation of
RUNX1DEx6 (Figures 32, 33). To further assess to the functional relationship between RUNX1
splicing and hnRNP K expression, we performed a series of knockdown and rescue experiments
in human cell lines.

In K562s, three shHNRNPK constructs were used to create stable

tetracycline-inducible lines. Indeed, knockdown of hnRNP K was evident at the RNA and protein
level 24-hours after doxycycline induction (Figures 34A, B). Importantly, RT-PCR revealed a
decrease in RUNX1DEx6 in the context of hnRNP K knockdown (Figure 34C). A concomitant
increase in full length RUNX1 was also evident. This is consistent with recently published data
in this cell line.149
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Figure 34. Knockdown of hnRNP K in K562 increases RUNX1 exon 6 inclusion.

A.

HNRNPK qRT-PCR in K562 stably infected with the indicated constructs treated with doxycycline
for 24 hours. Ex10 construct targets HNRNPK in exon 10, while ex16-1 and ex16-2 constructs
target the 3’ UTR of HNRNPK. B. Western blot of the cell lines used in A induced with
doxycycline for 24 hours. C. RUNX1 RT-PCR of the same cell lines. PPIA is used as a loading
control.

Add-back of hnRNP K to an shHNRNPK cell line rescues RUNX1 splicing alterations
Since the shHNRNPK Ex16-2 construct induced significant knockdown by targeting the
3’ UTR, we used this line to create another stable cell line with exogenous hnRNP K lacking this
targeted region. Therefore, we could use these cells as a tool to ‘rescue’ phenotypes associated
with a decrease in hnRNP K expression. As expected, in K562 cells, this resulted in hnRNP K
95

protein expression that approximated that of wildtype controls (Figure 35A).

Remarkably,

RUNX1 RT-PCR in cells with rescued hnRNP K expression also mimicked wildtype (Figure 35B).
This finding was echoed in OCIAML3 cells (Figure 35C). These findings indicate that alterations
in hnRNP K expression are sufficient to alter splicing of RUNX1 exon 6.

Figure 35. Addback of hnRNP K to shHNRNPK cells rescues RUNX1 splicing. A. Western
blot of K562 cells infected with empty vector (EV), hnRNP K overexpression (hnK OE), or either
of those in addition to shHNRNPK ex16-2. Cells were treated with doxycycline for 24 hours prior
to harvest. B. RUNX1 RT-PCR in K562 cells. C. RUNX1 RT-PCR in OCIAML3 cells. Samples
are ordered from lowest to highest hnRNP K expression, indicated by the black triangle.
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RUNX1DEx6 is translated
Since the known function of RUNX1 is as transcription factor, we sought to evaluate
whether RUNX1DEx6 had a corresponding protein product with similar function. To assess
whether RUNX1DEx6 was translated, we performed western blots of cell lines overexpressing
hnRNP K.

These revealed the presence of a smaller protein product (Figures 36A, B).

Compared to empty vector controls, this smaller protein product (~45 kDa), was more abundant
in cell lines overexpressing hnRNP K. Since the RUNX1DEx6 isoform is 192bp (encoding 64
amino acids), shorter than the full-length form (Figure 33), this size difference lends credence to
the conclusion that this smaller protein product is RUNX1DEx6. Strikingly, in cells with decreased
hnRNP K, this isoform was undetectable (Figure 36C).

Figure 36. A smaller RUNX1 isoform corresponds with hnRNP K expression at the protein
level. Western blots of A. K562 or B. OCIAML3 cells stably infected with empty vector (EV) or
hnRNP K overexpression (hnK OE) treated with doxycycline for 24 hours. C. Western blot of
OCIAML3 cells stably infected with shCtrl or shHNRNPK ex10 and treated with doxycycline for
24 hours. Red arrows indicate the smaller isoform of RUNX1 that appears at ~45 kDa.
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RUNX1DEx6 is present in AML patient samples
In Chapter 2, we identified that hnRNP K is overexpressed in AML. Given the data in this
chapter that overexpression of hnRNP K leads to an increase in RUNX1DEx6, we examined AML
patient samples for the presence of this isoform. While full-length RUNX1 was abundant in
healthy bone marrow and peripheral blood samples, expression of this isoform was drastically
reduced in nearly every case of AML (Figure 37). Instead, RUNX1DEx6 was the dominant
isoform expressed. This is a crucial finding, as the association of RUNX1DEx6 with AML
supports the clinical relevance of this entity.

Figure 37. RUNX1ΔEx6 is present in AML patient samples. RUNX1 RT-PCR from bone
marrow (left) and peripheral blood (right) of healthy human control donors or AML patient
samples. PPIA is used as a loading control.

Runx1DEx6 is present in mice transplanted with hnRNP K-overexpressing FLCs
Thus far, our data have shown that hnRNP K overexpression leads to an enrichment of
Runx1DEx6 in murine FLCs (RNA-Seq and RT-PCR; Figures 32, 33) and RUNX1DEx6 in human
AML cell lines (RT-PCR, western blot; Figures 34, 36). In addition, patients with AML also
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express RUNX1DEx6 (RT-PCR; Figure 37). To further evaluate how hnRNP K overexpression
influences this splicing in vivo, we evaluated Runx1 expression in the mouse model described in
Chapter 3. In spleen and bone marrow of mice transplanted with FLCs overexpressing hnRNP
K, there was a substantial enrichment of Runx1DEx6 at the expense of full-length Runx1 (Figure
38A).

At the protein level, before transplantation (Figure 38B) and in the spleen after

transplantation (Figure 38C), higher protein expression of Runx1DEx6 was evident. As expected,
these findings corresponded nicely with hnRNP K overexpression.

Figure 38. FLCs overexpressing hnRNP K have more Runx1ΔEx6. A. Runx1 RT-PCR from
spleen (left) or bone marrow (right) of mice transplanted with empty vector control FLCs or
hnRNP K-overexpressing FLCs. B-C. Western blots of FLCs pre-transplant (B) or from spleen
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of representative mice (C) transplanted with FLCs overexpressing empty vector or hnRNP K.
Red arrow denotes Runx1DEx6.

RUNX1DEx6 is more stable than full-length RUNX1
To begin evaluating the functional consequences of RUNX1DEx6, we compared the
stability of this protein isoform to that of full-length RUNX1. Adding cycloheximide to eukaryotic
cells impairs ribosomal translocation, thereby inhibiting cytosolic translation.245, 246 Since de novo
protein synthesis is dramatically hindered in the presence of cycloheximide, western blotting can
be used to visualize protein degradation over time. Proteins that degrade more quickly (decrease
in intensity on western blot) are said to be less stable than proteins that maintain expression for
longer periods of time in the presence of cycloheximide.247 Cycloheximide chase assays showed
that RUNX1DEx6 was substantially more stable than its full length counterpart (Figure 39A).
Consistent with this observation, addition of MG132, an inhibitor of proteasomal degradation,
stabilized full-length RUNX1, but had no effect on RUNX1DEx6 (Figure 39B), indicating that the
proteasomal pathway is responsible for degradation of full-length RUNX1. While RUNX1DEx6
is present in relatively low quantities in cells, its long half-life may allow for biologic consequences
despite low expression.

These data are consistent with reports that exon 6 contains

ubiquitination sites that target RUNX1 for proteasomal degradation.248
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Figure 39. RUNX1DEx6 is more stable than full-length RUNX1. Western blot of 293T cells
with stably integrated tetracycline-inducible RUNX1 (full-length or DEx6) were treated with
doxycycline for 24 hours prior to addition of A. cycloheximide (CHX) or B. CHX and MG-132 for
up to 8 hours. HSP90 is used as a loading control. Molecular weight ladder is marked in black
marker in panel B.

RUNX1DEx6 has differential transcriptional activity compared to full length RUNX1
The predominantly known function of RUNX1 is as a transcription factor. To further
investigate whether RUNX1DEx6 has biologic function, we examined its transcriptional
capabilities using luciferase reporter assays with an artificial RUNX1 reporter containing 13
consensus RUNX1 binding sites. We observed that cells transfected with full-length RUNX1
dramatically repressed luciferase activity; however, cells with RUNX1DEx6 had diminished
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capability to repress luciferase activity (Figure 40B). Addition of SIN3A, a transcriptional corepressor that binds RUNX1 within a region encoded by exon 6, also demonstrated differential
impact on full-length RUNX1 compared to RUNX1DEx6 (Figure 40C). This suggests that the
lack of exon 6 interferes with the ability of SIN3A to interact with RUNX1, and supports the notion
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that RUNX1DEx6 has altered transcriptional activity compared to full-length RUNX1.

Figure 40. Full-length RUNX1 and RUNX1DEx6 have differential transcriptional activity. A.
RUNX1 RT-PCR in 293T cells transfected with RUNX1 full length (FL) or DEx6 overexpression
plasmids B. Luciferase assays performed in 293T cells transfected with luciferase reporter
construct and empty vector (Ctrl) or increasing concentrations of full length RUNX1 or
RUNX1DEx6. RUNX1 concentrations range from 0.0625µg to 0.5µg.

C. Luciferase assays

performed in 293T cells transfected with luciferase reporter construct and empty vector (Ctrl) and
0.0625µg of RUNX1 with or without exon 6 as well as 0.5µg of SIN3A.
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The KH3 domain of hnRNP K mediates RUNX1 splicing
The previous data suggest that RUNX1DEx6 has different biologic function than its fulllength counterpart. Since the presence of RUNX1DEx6 is hnRNP K-dependent, we sought to
examine whether a particular domain of hnRNP K was responsible for this splicing. To this end,
we transfected 293T cells with constructs lacking sequential domains of HNRNPK.

When

RUNX1 splicing was evaluated in these lines, cells overexpressing any form of HNRNPK had a
near complete elimination of the full-length RUNX1 in favor of RUNX1DEx6, except those lacking
the KNS or KH3 domain (Figure 41A).

In these cells transfected with HNRNPKDKNS or

HNRNPKDKH3, splicing of RUNX1 was nearly identical to cells transfected with an empty vector
control.
To evaluate this phenomenon in another cell line, we made K562 cells stably transduced
with tetracycline-inducible overexpression of hnRNP K with deletions of the KH1, KH2, KI, or
KH3 domain.

When overexpressing these constructs, only those lacking KH3 showed a

reversion to splicing like that of the empty vector control (Figure 41B). The data from these two
cell lines thus strongly suggest that KH3 is the domain of hnRNP K that mediates inclusion of
RUNX1 exon 6.

Figure 41. KH3 domain of hnRNP K mediates RUNX1 exon 6 splicing. RT-PCR of RUNX1
from A. 293T cells transfected for 24 hours with the indicated flag-tagged hnRNP K constructs
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or B. K562 cells with tetracycline-inducible expression of the indicated hnRNP K constructs.
K562 cells were treated with doxycycline for 24 hours before RNA was harvested. Deletion
constructs are arranged in the order in which the functional domains occur within hnRNP K from
amino to carboxy terminus of hnRNP K. EV: empty vector control. PPIA is used as a loading
control.

The KH3 domain of hnRNP K is required for hnRNP K-overexpressing phenotypes in vitro
Since it appears that the KH3 domain of hnRNP K is largely responsible for mediating
RUNX1 splicing, we wanted to evaluate whether this domain contributed to the ability of hnRNP
K-overexpressing FLCs to form colonies in vitro. Compared to those overexpressing full-length
hnRNP K, FLCs overexpressing hnRNP K without KH3 had substantially decreased colony
formation (Figure 42). Strikingly, cells with hnRNP KDKH3 formed even fewer colonies in vitro
than empty vector controls. Together, these data indicate that hnRNP K-mediated increase in
Runx1DEx6 is critical to the in vitro phenotypes associated with hnRNP K overexpression.
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Figure 42. The KH3 domain of hnRNP K is required for an in vitro phenotype associated
with hnRNP K overexpression. Bar graph of the number of hematopoietic colonies formed per
well from FLCs stably transduced with empty vector (black), full-length hnRNP K (red), or hnRNP
K lacking the KH3 domain (blue). Cells were sorted for GFP expression to ensure stable
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integration of the viral construct. Note: This figure includes empty vector and hnRNP K OE data
points that were included in figure 12.

hnRNP K influences RUNX1 and global translation
In addition to the increase in RUNX1DEx6 observed with hnRNP K overexpression, it was
evident that total RUNX1 protein expression also increased in this setting (Figures 36, 38). Given
the binding of hnRNP K to the 5’ UTR of RUNX1 identified in Chapter 4 (Figures 26, 28, 29), and
the interaction between hnRNP K and ribosomal subunits identified in Chapter 4 (Figure 23), we
sought to evaluate whether hnRNP K influenced translation of RUNX1. The notion that hnRNP
K regulates RUNX1 expression at a post-transcriptional/translational level is supported by the
observation that total RUNX1 RNA is not increased in hnRNP K-overexpressing cells (Figure
43A).
To more directly address this question, we performed polysome fractionation assays. In
these experiments, ribosomal subunits and their associated mRNAs are segregated based on
density in a sucrose gradient. Fractions of this gradient are inspected by a spectrophotometer
to assess absorbance at 260nm. By tracing these absorbances over each fraction, we can
produce the beloved “polysome trace”, representing an overview of a global translational profile
for a given population of cells. Furthermore, RNA from these individual fractions can be isolated
and analyzed by qRT-PCR to measure translation of an individual RNA species.
Knockdown of hnRNP K in 293T cells resulted in a marked change in the global polysome
trace (Figures 43B, C). Cells with decreased hnRNP K showed a substantial spike in the 80S
(monosome) fraction compared to controls.

Polysomes are traditionally deemed as the

translationally active components, as this is where the majority of new peptide bonds are
formed.249-251 Thus, as monosomes accumulate in cells, translation generally becomes less
active at a global scale, likely due to mRNA loading difficulties. Therefore, decreased hnRNP K
results in less active translation.
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To specifically evaluate the translational status of RUNX1, we performed qRT-PCR on
the individual fractions comprising the polysome trace. Compared to cells transfected with a
scrambled control, cells with decreased hnRNP K had less RUNX1 in the 80S monosome fraction
(Figure 43D). Given that there was not a compensatory increase of RUNX1 in the low-molecular
weight and high molecular weight polysome fractions, this suggests that RUNX1 may fail to load
into complete ribosomal subunits in the absence of hnRNP K.

106

siHNRNPK

A

C

1.25

hnRNP K
β-actin

0.50

40S

60S

LMW

HMW

0.25
0.00
-0.25

80

0

10

20

30

40

50

Position (mm)

60

70

80

90

siScr
siHNRNPK

60
80

siScr

*

40
60

siHNRNPK

om

e

W

W

ly
s

ol
ys

M
H

W
LM

S
80

S

om
e Po

H

LM

M

W

S
80

S
60

S
60

40

ou
nb

S

0

nd

U

nb

40

0
20

nd

20
40

ou

% RUNX1
% mRNA
RUNX1 mRNA

siScr
siHNRNPK

0.75

-0.50

D

80S

1.00

Absorbance (normalized)

siScr

B

P

U

Figure 43. hnRNP K alterations affect global translation and that of RUNX1. A. qRT-PCR
for total RUNX1 in the indicated cell lines overexpressing hnRNP K or empty vector. Cells were
treated with doxycycline for 24 hours prior to harvest. Primers in this reaction spanned exons 34 of RUNX1, thus measuring the total level of transcript independent of spliced products. B.
Western blot of 293T cells transfected with siScramble control (siScr) or siHNRNPK for 72 hours.
C. Polysome trace of 293T cells transfected as in panel A. X-axis represents the fraction of
sucrose gradient collected as a position of the length of the physical gradient (nm). Y-axis
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represents the absorbance of the fraction at 260nm normalized to a no protein control. Fractions
are labeled according to the accepted location of peaks for 40S, 60S, and 80S ribosome
fractions.

LMW= low-molecular weight; HMW= high-molecular weight polysome fractions.

Traces from four individual experiments are superimposed in this graph. D. RUNX1 qRT-PCR
from fractions collected in panel B. Portions of this figure were modified with permission from
Gallardo & Malaney et al., JNCI, 2019.83
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5.4 Discussion
In this chapter, we identified that hnRNP K overexpression altered genome-wide RNA
splicing. Strikingly, Runx1 emerged as one of the most differentially spliced transcripts in this
setting (Figure 31). This observation, along with the data in Chapter 4 that hnRNP K stringently
and specifically bound human and mouse RUNX1 at intron 5-6, and the role of RUNX1 as a key
transcription factor in leukemia, we specifically honed in on the interaction between hnRNP K
and RUNX1.
The impact of hnRNP K on splicing of individual transcripts has been described.56, 58, 59,
150, 151

However, to our knowledge, genome-wide analyses of splicing alterations occurring in the

context of differential hnRNP K expression has not been described. While we focused on
RUNX1, these global analyses certainly provide insights for future inspection of the role of hnRNP
K in hematopoietic splicing.
Our observations that hnRNP K reduction leads to inclusion of exon 6 is in line with what
others have briefly identified.56, 149 However, these prior observations have been made in the
context of hnRNP K knockdown. To our knowledge, we are the first to show that overexpression
of hnRNP K results in RUNX1 exon 6 exclusion. This was a critical finding given our observation
that this isoform is readily identifiable in AML patient samples (Figure 37).

Unlike other

alternatively spliced isoforms of RUNX1, RUNX1A and RUNX1B, the isoforms we studied are
expected to be identical in their C terminal domains. In addition, we are confident that what we
refer to as RUNX1DEx6 is not merely RUNX1A, as RUNX1A: 1) lacks exon 7, where our reverse
primer for splicing PCR is placed and 2) has a predicted molecular weight of ~27kDa—
substantially less than the observed ~45kDa for RUNX1DEx6.
Functional consequences due to loss of a single exon are biologically plausible. The
amino acid residues encoded in exon 6 of RUNX1 comprise a negative regulatory region, where
SIN3A, a corepressor, binds.252 This region also limits RUNX1-DNA interactions253. We showed
that RUNX1DEx6 had differential transcriptional activity compared to its full-length counterpart
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(Figure 40). Our data suggest that this is due in part to altered cooperativity with SIN3A (Figure
40B). Though we did not formally test the DNA-binding affinity of RUNX1DEx6 compared to fulllength RUNX1, one group identified murine Runx1DEx6 as having increased DNA binding
affinity.93 Consistent with that observation, another group described RUNX1DEx6 as having
dominant negative activity over RUNX1 when evaluated in a human ovarian cancer cell line.155
More complete evaluation of the transcriptional differences between full-length RUNX1 and
RUNX1DEx6 in AML is ongoing in our laboratory.
In addition to altered transcriptional activity, we also observed increased stability of
RUNX1DEx6 compared to full-length RUNX1 (Figure 39). This is consistent with observations
of murine Runx1 lacking this exon.88 Since exon 6 contains two ubiquitination sites248, the
absence of these sites in RUNX1DEx6 may explain this apparent increase in protein stability.
To gather more insight into the mechanism of this hnRNP K-dependent RUNX1 exon 6
splicing, we narrowed down domains of hnRNP K that appeared to be critical for this
phenomenon. Absence of the KH3 domain had a striking effect on the inclusion of exon 6, and
reverted splicing to near wildtype levels (Figure 41).

In support of this observation, early

descriptions of hnRNP K described poly(C) binding as mediated largely by KH3.153 However,
other groups have concluded that all KH domains play a role in poly(C) binding.74
Deletion of the KH3 domain in hnRNP K largely rescued RUNX1 splicing (Figure 41) and
also abrogates an in vitro phenotype associated with hnRNP K overexpression (Figure 42). Of
note, the KH3 domain of hnRNP K can bind ssDNA acid as a single domain254, and is the only
portion of the protein in which a crystal structure has been determined (in complex with
ssDNA).255 This could be of particular interest from a therapeutic standpoint for several reasons.
First, given the myriad of biologic functions of hnRNP K, completely eliminating this protein would
likely be extremely toxic. Indeed, Hnrnpk knockout mice are not viable.53 Second, hnRNP K has
multiple functional domains, so understanding which domain to target could expedite drug
discovery while also mitigating potential toxicity. Finally, the existing crystal structure of the KH3
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domain may expedite drug development, as this can be used for computer-based predictive drug
discovery models and can also be used to structurally optimize compounds identified in cellbased assays.
Our studies did not evaluate other splicing factors in the context of hnRNP K
overexpression.

It has been shown that hnRNP K competes with U2AF2 (also known as

U2AF65) for binding at poly(C) tracts near 3’ splice sites, like that near the Runx1 intron 5-6
junction.56 Little is known about how hnRNP K itself regulates splicing factors, though this is
certainly a topic of great interest given the impact of hnRNP K on splicing alterations.
Given the vast array of hnRNP K-involved biologic processes, it seems unlikely that
hnRNP K overexpression is oncogenic by means of a single mechanism. To begin evaluating
these other mechanisms, we briefly evaluated hnRNP K’s translational properties. Indeed, our
polysome studies indicated that hnRNP K alterations globally affect translation (Figure 43).
Specifically, this results in disrupted translation of RUNX1. We were not able to evaluate
translation of full-length RUNX1 compared to RUNX1DEx6, but this would certainly be of interest.
Given the hnRNP K binding to the 5’ UTR of RUNX1 (Figures 26, 28, 29), we anticipate that there
would be no difference between these isoforms. It is also notable that while hnRNP K clearly
bound the 5’ UTR of human RUNX1 (Figure 28, 29), this hnRNP K binding site was absent in
murine Runx1. However, hnRNP K overexpression still resulted in increased protein expression
of total Runx1 in mouse (Figure 38). The mechanisms underlying this observation are unclear,
but may be due to hnRNP K’s global modulation of translation.
Together, our studies indicate that hnRNP K mediates splicing and translation of RUNX1,
and overexpression of hnRNP K results in an enrichment of RUNX1DEx6 in mouse and (wo)man.
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Treatment of acute myeloid leukemia (AML) is evolving at an unprecedented pace due to
development of drugs targeting actionable genetic lesions. This therapeutic renaissance has
dramatically improved outcomes for many patients with AML. However, many individuals do not
harbor these targetable alterations, or relapse by various mechanisms. Therefore, it is imperative
to identify novel mechanisms controlling the fundamental biologic processes underlying
leukemogenesis and to develop therapies that target these vital nodes of dysregulated
proliferation, survival, and/or differentiation. To this end, our laboratory has adopted a multistep
approach to identify novel alterations driving hematologic malignancies. Accordingly, we have
identified hnRNP K, an RNA-binding protein, as a novel driver of these diseases through its
regulation of critical oncogenes required for cell growth, survival, and differentiation. This body
of work focuses on the oncogenic role of hnRNP K in AML.
In Chapter 2, we identified overexpression of hnRNP K in acute myeloid leukemia and
observed that this overexpression was associated with inferior outcomes, including decreased
remission durations and overall survival (Figure 5). These data allude to an oncogenic role for
hnRNP K when overexpressed.
Consequently, we identified overexpression of hnRNP K as a driving event underlying
myeloproliferation in an in vivo mouse model in Chapter 3. Our data indicate that elevated
hnRNP K expression is pathologic; however, the mechanisms underlying the observed
overexpression of hnRNP K are still unclear. Many cases of AML harbored an additional copy
of the HNRNPK locus identified by FISH (Figure 10). These additional copies were not part of
any known chromosomes, indicating that the extra copies may exist as sSMCs. Beyond the
HNRNPK locus, the contents of these so-called sSMCs were not identified. While these cases
also had increased hnRNP K protein expression, it remains unclear whether the HNRNPK locus
on the sSMC is transcriptionally active. Identification of the regulatory elements in these sSMCs
may shed light on mechanisms of endogenous HNRNPK regulation in diseased states.
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It is also possible that increased hnRNP K expression may be due to trans effects—where
alterations at another genomic location (e.g., mutated or deleted transcription factors, altered
epigenetic regulators, etc.) influence expression of a gene at a distant locus.256 One group
recently reported that in AML cases with del(9q) (usually associated with HNRNPK
haploinsufficiency), those with co-occurring mutations in the transcription factor CEBPA had near
normal HNRNPK RNA expression; del(9q) cases with unmutated CEBPA had low HNRNPK
expression.257 Given the necessity of hnRNP K at an organismal level53, as well as the array of
tumor types associated with its overexpression75-82, identifying the regulation of this oncogene
would be worthy of future pursuit. Indeed, several high-throughput methods now exist to evaluate
possible trans effects on a more global scale.258, 259
To evaluate the consequences of hnRNP K overexpression in vivo, we developed a
mouse model in Chapter 3. These mice had reduced survival and developed myeloproliferative
phenotypes.

This model utilized retroviral transduction of fetal liver cells transplanted into

recipient mice. During the course of the current studies, we also developed transgenic models
of hnRNP K overexpression using both constitutive and conditional expression in the
hematopoietic system. While these mice exhibited gross hematopoietic abnormalities, they failed
to maintain reliable overexpression of the hnRNP K protein, thereby confounding the role of
hnRNP K in disease pathogenesis in these systems. In contrast, overexpression of hnRNP K in
fetal liver cells was substantially more consistent. Whether this is due to a technical aspect of
stable viral integration or is an effect secondary to altering cells during a different stage of
organismal development remains unclear. This once again highlights a need to understand
regulation of hnRNP K expression in vivo.
In our mouse model of hnRNP K overexpression, the disease phenotypes were
exclusively myeloid in nature (Chapter 3). While these mice developed phenotypes substantially
similar to those seen in Hnrnpk+/- mice, a percentage of Hnrnpk+/- animals developed lymphoid
malignancies.53

Further supporting a role for hnRNP K in lymphoid development and
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lymphomagenesis, mice overexpressing hnRNP K in B-cells develop overt lymphomas.83 These
observations demonstrate that altered hnRNP K expression, in either direction, can influence
hematopoiesis. As Hnrnpk null mice die in utero53, evaluation of hematopoiesis in these embryos
may elucidate the most fundamental roles of hnRNP K in blood development. Interestingly,
children with germline HNRNPK mutations, presumed to be inactivating insults, do not have
grossly observable hematopoietic defects.38, 167, 260
Several large-scale global analyses were performed to elucidate the oncogenic basis of
hnRNP K overexpression in myeloid disease. Consequently, we identified that the oncogenicity
of hnRNP K may be attributed to its RNA-binding activities. hnRNP K stringently and specifically
binds RNA, leading to altered splicing of genes such as RUNX1. We further showed that the
KH3 domain of hnRNP K was largely responsible for mediating this splicing alteration (Figure
41), and that deletion of KH3 abrogated the effects of hnRNP K overexpression (Figure 42).
Previous reports have concluded that the RNA-binding function of hnRNP K is mediated through
cooperative activity of its three KH domains, and binding is abrogated when any domain is
disrupted.74, 217 Therefore, we anticipated that loss of any KH domain would alter these splicing
effects. We instead identified KH3 as the key domain mediating RUNX1 splicing. This finding
was particularly compelling, as it suggests that these KH domains have varied roles in nucleicacid directed processes. Furthermore, these findings place the KH3 domain as being critical in
the phenotypes described in this work.
The observation that hnRNP K overexpression results in altered splicing of RUNX1,
enriching for an isoform with altered transcriptional activity (RUNX1DEx6), is a captivating finding,
as disrupted RUNX1 transcriptional programs have been shown to contribute to
leukemogenesis.261,

262

In RUNX1DEx6, the DNA-binding domain of RUNX1 is predicted to

remain intact, since the Runt-homology domain (RHD) is upstream of exon 6.263 However, the
interaction with transcriptional co-factors and the regulation of this isoform could feasibly
contribute to leukemogenesis. Indeed, expression of only the RUNX1 RHD, which lacks many
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of the regulatory elements of RUNX1, is sufficient to cause myelodysplastic syndrome in mice.261
The lack of exon 6 described in our studies may result in broadly altered RUNX1-mediated
transcription. Evaluation of the transcriptome landscape of cells enriched for RUNX1DEx6 will
be useful in clarifying this point. To this end, our laboratory is pursuing RNA-sequencing as well
as chromatin immunoprecipitation followed by sequencing (ChIP-Seq) of RUNX1DEx6overexpressing cells.
Well-characterized alterations in RUNX1 transcriptional programs are perhaps best
exemplified by those observed in core-binding factor acute myeloid leukemia (CBF-AML). Many
cases of CBF-AML harbor t(8;21)15, which encodes a fusion protein known as RUNX1-RUNX1T1
(also called AML1-ETO or RUNX1-CBFA2T1)16. While globally, RUNX1-RUNX1T1 binds to
similar genomic locations as RUNX1, vast transcriptional alterations are observed.264, 265
The breakpoint within RUNX1 involved in t(8;21) most commonly occurs in the intron
spanning exons 5 and 6.266, 267 However, these breakpoints are almost invariably located 5’ to
the hnRNP K binding site, though rare instances of RUNX1-RUNX1T1 containing RUNX1 exon
6 have been reported.268 Thus, hnRNP K is unlikely to be directly involved in alternative splicing
of the RUNX1 portion of this gene product. However, we have not evaluated the possibility that
hnRNP K alters splicing of RUNX1T1, though preliminary analysis did not identify putative
hnRNP K binding sites in this gene. Given that several splice variants of RUNX1-RUNX1T1 have
been reported269-271, future studies in this area may be worthwhile.
Our initial evaluation has determined that the hnRNP K binding site in the 5’ UTR of
RUNX1 is, however, maintained in the most common forms of t(8;21), suggesting that hnRNP K
may be involved in RUNX1-RUNX1T1-associated leukemogenesis. Interestingly, in cases of
t(8;21) AML, deletions of chromosome 9q have been observed as a common secondary
abnormality271-273, further alluding to a role for hnRNP K in this disease. To begin evaluating this
scenario, we have added overexpression of RUNX1-RUNX1T1 to our hnRNP K-overexpressing
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fetal liver cells prior to transplant in recipient mice. These mice develop frank transplantable
leukemia, though the relative impact of hnRNP K in this setting is not yet clear. Continuation of
these studies to evaluate the interaction between hnRNP K and RUNX1-RUNX1T1 may provide
valuable insight into this disease.
Given the data presented in Chapter 5 that hnRNP K alters splicing of not only RUNX1,
but also other genes involved in leukemia, it would be of great interest to assess the mutational
status of splicing factor genes in these cases and others that overexpress hnRNP K. While
mutations in SF3B1, SRSF2, and U2AF1 are mutually exclusive events in cancers, including
AML143, 274, 275, identification of hnRNP K overexpression as yet another mutually exclusive event
would strongly indicate that a major mechanism of hnRNP K’s oncogenicity stems from its
deleterious effects on alternative splicing. Furthermore, comparing splicing alterations in AML
patients with hnRNP K overexpression to splicing alterations in patients harboring splicing factor
mutations could also shed light on recurrently altered splicing events that may underlie
leukemogenic transformation.
In light of the vast array of cellular processes in which hnRNP K appears to be involved,
the possibility that hnRNP K exerts oncogenic functions through mechanisms beyond altered
splicing of RUNX1 must be acknowledged. Consistent with this sentiment, mice exclusively
expressing Runx1DEx6 exhibit aberrant hematopoiesis, but do not develop leukemia.149 In our
previous work evaluating hnRNP K-overexpression in the setting of B-cell lymphomas, disease
was driven largely via hnRNP K’s interactions with MYC, where it stabilized the MYC transcript
and promoted c-MYC translation.83 While we did not extensively evaluate the hnRNP K-MYC
interaction in the current studies, it remains possible that MYC alterations could contribute to the
observed phenotypes. Indeed, our collaborators have described c-MYC overexpression as an
important prognostic factor in AML.276 Furthermore, hnRNP K overexpression resulted in global
gene expression and splicing alterations—underscoring the notion that altered RUNX1 splicing
may only represent a portion of the oncogenic facets of hnRNP K overexpression.
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To provide a therapeutic output for our findings, work is currently underway in our
laboratory to screen compounds that kill leukemia cells in an hnRNP K-dependent manner. As
splicing inhibitors have been used in early clinical trials277, 278, understanding a specific context
for using these drugs is beneficial.

These experiments will evaluate whether hnRNP K-

overexpressing AML cells—harboring vastly altered splicing—are more sensitive to splicing
inhibitors than cells with average hnRNP K expression. Given that hnRNP K is itself a splicing
inhibitor, effects seen with these drugs may represent a synthetically lethal relationship279.
Given the oncogenic properties of hnRNP K when overexpressed (Chapter 3, Gallardo &
Malaney et al., 201983), it is logical that targeting this protein directly may have therapeutic
benefit. While no specific inhibitors of hnRNP K are currently available, few compounds have
been reported to modify hnRNP K-dependent processes.280 Since the RNA-binding properties
of hnRNP K appear to be most central to its oncogenic functions—whether mediating splicing
(RUNX1; Chapter 5), or mRNA stability and translation (RUNX1, Chapter 5; MYC83)—disrupting
this interaction is a viable approach for drug development. To this end, our laboratory is currently
utilizing fluorescence anisotropy assays (Figure 28) as screening tools to evaluate the capability
of small molecule compounds to disrupt hnRNP K-RNA interactions. Presently, several lead
compounds have emerged that appear to effectively interrupt these interfaces. Ongoing work in
developing a drug to inhibit hnRNP K-RNA interactions is an exciting venture, as patients with
AML (Chapter 2) and DLBCL83 overexpressing hnRNP K have shortened overall survival.
Compounds that inhibit hnRNP K-RNA interactions may also find substantial utility
outside of oncology. For example, replication of Influenza A virus requires the splicing activity of
hnRNP K; depletion of hnRNP K reduces the pathogenicity of this ubiquitous virus.59, 154 In
human immunodeficiency virus-1 (HIV-1), hnRNP K acts as an inhibitory splicing factor.281
hnRNP K has been implicated in viral pathogenesis of numerous other RNA viruses, including
enterovirus 71 (EV71)282, dengue283, chikungunya284, sindbis285,

hepatitis B (HBV)286, and

hepatitis C (HCV)287. Interestingly, some of these viruses, such as HBV and HCV, have known
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roles in oncogenic transformation.288,

289

Therefore, inhibiting hnRNP K’s RNA-directed

processes may also be beneficial in virally-induced cancers. Interestingly, hnRNP K has been
implicated in the life cycles of several DNA viruses, as well. These include herpes simplex virus1 (HSV1)290, Epstein-Barr virus (EBV)291, cytomegalovirus (CMV)292, and African swine fever
virus293.

Indeed, EBV can cause lymphoma294, thereby indirectly linking hnRNP K to

hematopoietic oncogenesis. However, in the case of human papillomavirus (HPV), an oncogenic
DNA virus, hnRNP K appears to inhibit translation of viral proteins, suggesting it may have antiviral activity in this context.65 This emphasizes that hnRNP K’s activities can vary according to
the particular cellular context.
In support of the notion that hnRNP K can directly promote cellular growth programs in
tumor cells as well as promote viral infection, hnRNP K was the first described human pangranzyme substrate.295 This apparent dire desire to cleave and destroy this protein supports
claims that hnRNP K is often pathogenic—particularly in high amounts. Indeed, knockdown of
hnRNP K sensitizes tumor cells to death mediated by cytotoxic lymphocytes.295
Altered hnRNP K may directly or indirectly result in immunologic consequences that may
predispose organisms to infection and/or inflammatory milieus. As described above, hnRNP K
may influence a cell’s propensity to viral infection—which can itself be oncogenic. Of note,
hnRNP K plays a role in several immunological processes. For example, hnRNP K is required
for the DNA cleavage involved in B-cell somatic hypermutation and class switch
recombination.296 While these processes are inhibited with depletion of hnRNP K, the impact of
hnRNP K overexpression has not been defined. In T-cells, hnRNP K has been identified as an
important target of ERK signaling and subsequent IL-2 production.297 Again, to our knowledge,
hnRNP K overexpression has not been studied in this context. In uninduced macrophages,
hnRNP K has been shown to translationally repress central downstream components of TLR4
signaling, acting to basally repress secretion of inflammatory cytokines.298 In the context of
hnRNP K overexpression, it is feasible that such a repressive effect may be exaggerated, and
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thus greater stimuli required to achieve an appropriate inflammatory response. We did not
evaluate the role of hnRNP K overexpression on the functions of these immune cells in our
mouse models. Thus, it is possible that the myeloproliferative phenotypes we observed were
secondary to a vastly dysregulated immune system. Evaluating the functional capabilities of
component immune cells in these mice may help clarify the sincerity of this possibility.
Additionally, future studies involving infection challenges or in-depth analysis of the cytokine
levels in these mice would be of interest.
Understanding the biology underlying hematopoietic disease, including AML, is what
fundamentally allows for development of effective therapeutic modalities. Findings from our
studies have substantially advanced our knowledge regarding the clinical relevance and in vivo
functions of hnRNP K and its interactions with RUNX1. Additionally, these studies have led to
the identification and understanding of mechanisms that drive hnRNP K-mediated
leukemogenesis and have determined how hnRNP K overexpression cooperates with RUNX1,
one of the most critical transcription factors in hematopoiesis. Given the overexpression of
hnRNP K in AML (Chapter 2), its ability to cause myeloid disease in mice (Chapter 3), and alter
RUNX1 splicing (Chapters 4, 5), we conclude that hnRNP K is an oncogene in AML that functions
in part via its interaction with and splicing regulation of RUNX1.
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